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 List of abbreviations 
  
ADME absorption, distribution, metabolism, excretion 
AKI(s) Aurora kinase inhibitor(s) 
ALL acute lymphoblastic leukaemia 
AML acute myeloid leukaemia 
ATCC American Type Culture Collection 
BRCA1 breast cancer 1 (protein) 
CI combination index 
CIN chromosomal instability 
CPC chromosomal passenger complex 
c-Met hepatocyte growth factor receptor 
DMSO dimethyl sulfoxide 
DNA desoxyribonucleic acid 
DTT dithiothreitol 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
EMT Epithelial-mesenchymal transition 
EVL Extended Validation Library™ 
Fa fraction affected (=activity) 
FAK focal adhesion kinase 
FBS foetal bovine serum 
FDA food and drug administration (US office) 
GnRH gonadotropin-releasing hormone 
GPCR G protein-coupled receptor 
HEPES 4-(2-hydroxyethyl)-1-piperazine-1- 
 ethanesulfonic acid (buffer) 
HER2 human epidermal growth factor receptor 2 
HGF hepatocyte growth factor 
HRP horseradish peroxidase 
IC50 inhibitory concentration at 50% effect 
INCENP inner centromere protein 
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KI(s) kinase inhibitor(s) 
KM Michaelis-Menten constant 
KMN Knl1 - Mis12 - Ndc80 (protein complex) 
MAPK mitogen-activated protein kinase 
MC mitotic checkpoint 
MR master regulator (protein) 
MTT 3-(4,5-dimethylthiazol-2-yl)- 
 2,5-diphenyltetrazolium bromide 
NCL Nested Chemical Library™ 
NSCLC non-small cell lung cancer 
PARP poly (ADP-ribose) polymerase 
PBS phosphate-buffered saline (solution) 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PI3K Phosphoinositide 3-kinase 
PI propidium-iodide 
PMSF phenylmethylsulfonyl fluoride 
PVDF polyvinylidene-difluoride 
rt room temperature 
RTKs receptor tyrosine kinase(s) 
SAR structure-activity relationship 
TAMRA carboxytetramethylrhodamine 
TBST tris buffered saline (solution) with 0.1% TWEEN 20 
TKI(s) tyrosine kinase inhibitor(s) 
VEGF vascular-endothelial growth factor 
VEGFR vascular-endothelial growth factor receptor 
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1. Introduction 
1.1. Cancer 
1.1.1. On cancer in general 
Abnormal tissue growth – tumour – is a common phenomenon in multicellular 
organisms. While benign tumours usually cause no harm, malignant tumours – cancers 
(from the Greek word for crab) – have the ability to detach from the originating tissue. 
These invading cancer cells then spread across the body via the blood and lymphatic 
current and create new tumours elsewhere – called metastases.1 These cancerous bodies 
crowd out normal cells and cause dysfunction of the invaded organs which eventually 
leads to the death of the patient. Nowadays cancer became one of the most prevalent 
cause of death in both developing (mainly because of environmental risks) and 
developed countries (mainly because of longer lifespan).2, 3, 4 
Cancers are highly heterogeneous in many aspects: 
- Regarding the tissue of origin, cancers can be classified into numerous histological 
types (carcinoma, leukaemia, melanoma etc.) that gives valuable information at the first 
glance.5 
- Cancer cells from different parts of a given tumour tend to utilize different 
metabolism.6 
- Like healthy cells, cancer cells might also differ in their potency to differentiate into 
specialised (cancer) cell types. This notion is an ever hotter topic – see the theory of 
cancer stem cells.7 
- Furthermore, there are always non-cancer cells in a tumour: endothelial cells build up 
the well-known amorphous vasculature of tumours,8 cancer-associated fibroblasts 
surround and interact with epithelial cancer cells9,10 also immune cells infiltrate tumours 
and either hinder or promote cancer progression.11 These cells constitute the tumour 
microenvironment that also able to modify drug response.12 
- However, in the last thirty years it has became clear, that various genetic alterations 
and mainly the resulted malfunctioning proteins – increased or lost activity – stimulate 
cancer cells to divide ceaselessly.13 The heterogeneity set up by these diverse genetic 
alterations not only explains the development of cancers but also conveys firm clues for 
therapy as well.14,15 Targeted pharmacological inhibition of the malfunctioning proteins 
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has already improved many cancer patient’s life expectancy.16 However, the list of 
potential target proteins is far from complete, and also many proved targets still lack an 
approved drug. 
1.1.2. Cancer as a genetic disease 
Genetic alterations occur naturally (mainly during DNA replication)17 but certain 
environmental factors – carcinogens (like viral infections, certain chemical compounds 
and high-frequency electromagnetic radiation (gamma and UVB rays)) – are able to rise 
their number through damaging the DNA. This way carcinogens raise the probability 
that a normal cell turns into a cancer cell.18 Some cancer-promoting genetic alterations 
can be inherited as well.19 
If too many DNA damages are accumulated, normal cells commit suicide – called 
apoptosis – or cease dividing for ever – called senescence –, in order to prevent the 
formation of genetic alterations that might lead to uncontrolled cell proliferation.20 If 
that does not happen and the DNA damage causes permanent genetic alteration that is 
able to abnormally stimulate, “drive” the proliferation of a cell, a cancer cell is born.21 
Regarding their origin, cancer driver genetic alterations can be: 
a) Mutations, alterations in the DNA sequence affecting rather few nucleotides 
(substitution, insertion, deletion). The majority of them affect no regulator or protein 
coding regions. A silent mutation does so, but without altering any function or protein 
sequence. Even mutation of a protein coding region that leads to amino acid change 
usually does not alter the function of the encoded protein – they are passenger 
mutations. However, if a controller region is spoiled the mutation results in an over- or 
under-expressed protein (and so increased or decreased activity of the pool of that 
protein).22 Similarly, if the swapped amino acid is crucial for protein function the 
mutation results in a malfunctioning translated protein with increased or decreased 
activity on its own.23 In both cases the affected gene becomes a mut-driver gene. 
b) chromosomal abnormalities of various scale are alterations in the DNA sequence 
affecting larger chromosomal segments (translocation, duplication or deletion) or even 
loss/gain of whole chromosomes compared to normal number – later phenomenon 
called aneuploidy. They might cause gene copy-number alterations (amplification or 
deletion) and new fusion genes.24 These alterations are also a source of over-, under-
expressed or fusion proteins with increased activity.21 
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c) Epigenetic alterations are actually not genetic phenomena since they affect no DNA 
sequence25 but usually affect the regulator regions of genes – resulting in over- or 
under-expressed proteins. The affected genes are epi-driver genes.26 
d) Aberrant RNA processing and splicing might also result in over- or under-expressed 
proteins.27 
Point c) and d) constitute the most elusive kind of genetic alterations which are hard to 
analyse by conventional sequencing methods. Therefore, most studies focus on sheer 
sequence alterations of DNA, especially mutations. 
Regarding function, driver genes fall into two groups: 
I) many genes and proteins stimulating normal cell growth, division and differentiation 
are proto-oncogenes. Provided a genetic alteration affects them, their activity increases 
and they become oncogenes. Oncogenes endow the cell with selective growth advantage 
compared to normal cells of the same tissue.21 
II) genes and proteins hindering cell growth, division and differentiation are tumour 
suppressors. Many of them induce apoptosis or senescence and their loss of function is 
which endows the affected cell with selective growth advantage.21 
Regarding effect, drivers concert seven important hallmarks of cancer cells.28 The first 
two are fundamental – so called enabling – characteristic in the progression of a cancer. 
The following five phenomena usually occur later but there is no invariant order of them 
and not every cancer cell displays all of them – e.g. benign tumours typically lack 
point 5).29 
1) sustained proliferative signalling is usually a result of increased activity of an 
oncogene, e.g. due to gene mutation or protein overexpression in case of EGFR 
(epidermal growth factor receptor) or due to gene amplification in case of c-Met 
(hepatocyte growth factor receptor). 
2) evasion of apoptosis – mainly due to decreased activity of tumour suppressors. 
However, as cancer cells continue to divide and the tumour mass grows, new challenges 
immediately arise. These obstacles surely eliminate most incipient cancers – or at least 
keep them in a few-cell, undetectable and harmless state: 
3) preserving telomeres. Telomere sequences protect chromosomes from stochastic 
breakage and fusion while shortening with each cell division.30 A critical length of 
telomeres induce apoptosis or senescence. For incipient cancer cells these repeated 
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breakage-fusion cycles create new – sometimes driver – genetic alterations.31 This is the 
well-known CIN (chromosomal instability) that further fosters – and eventually 
becomes the major source of – genetic heterogeneity found in cancers32 and indicates 
poor prognosis.33 Of course high CIN can be detrimental to cancer cells,34 so after a 
while telomere restoring enzymes – telomerases – are acitvated in about 90% of 
cancers.35 
4) induction of angiogenesis. As the tumour mass reaches a critical volume, it needs 
blood vessels to efficiently obtain nutrients and oxygen – similarly to healthy tissues. 
For this purpose, cancer cells need to express or increase the activity of pro-angiogenic 
molecules like: VEGFR (vascular-endothelial growth factor receptor), PDGFR (platelet-
derived growth factor receptor) and their natural ligands VEGF (vascular-endothelial 
growth factor) and PDGF (platelet-derived growth factor).36 
5) invasion and formation of metastasis. EMT (epithelial-mesenchymal transition) is 
the phenomenon when some differentiated epithelial cells break the cell-cell junctions 
and penetrate the basal membrane. The EMT program is normally active in embryonic 
cells37 or during wound healing.38 Cancers of epithelial origin often activate genes and 
proteins promoting EMT, detach from the basal membrane and invade neighbouring 
tissues.39 Apart from stochastic endogen cellular processes40 hypoxic tumour 
environment41 and certain drugs can also induce EMT.42 Unfortunately in cancer cells 
with active EMT program also anti-apoptotic signals are evoked and they become more 
resilient to treatment.43 However, many cancer cells do not survive amidst the shearing 
forces of blood or lymphatic current and only a fraction or them manage to colonise 
distant tissues.44 Established metastases then independently evolve to a new tumour.45 
According to the latest studies, there are no solid “metastasis genes or mutations” and 
metastasis occurs at a very early stage during cancer development.46  
6) Evading the immune system – solid cancers are known to be infiltrated by cells of 
innate and adaptive immunity: “tumours are wounds that never heal”.47 In fact, evading 
immune destruction by selection of less-immunogenic clones (displaying altered cell 
membrane proteins) might be an important step in cancer development, at which many 
incipient cancers fail.48 Paradoxically, immune destruction of cancer cells and the 
accompanying inflammation have tumour-promoting effect as well, because of the 
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secretion of angiogenic and survival factors and the breaking down of intracellular 
matrix (easing invasion).11 
7) Reprogramming energy metabolism. Incipient cancers often lack oxygen (see point 
4), thus they switch off oxidative phosphorylation and use only glycolysis to ferment 
glucose to lactate. Surprisingly, very often well-oxygenised cancers behave the same 
way – the phenomenon is called aerob glycolysis or Wartburg effect.6 The rationale is 
that upregulated glycolysis produces more intermediers (“building blocks”) for 
intensive cell growth. Also proliferation-inducing oncogenes are known to activate 
aerob glycolysis.49 
1.1.3. Comprehending the genetic heterogeneity of cancers 
The elevated number of genetic alterations found in a tumour mass originates from 
increased cell proliferation and CIN. It is important to note that there are no invariant or 
consensus genetic alterations in cancers of any histological type, rather more abundant 
ones in a given sample.50 Different parts of the same tumour (intratumoral 
heterogeneity) and even metastases of the very same primordial tumour (intrametastatic 
heterogeneity) harbour different genetic alterations.51 This genetic heterogeneity 
provides the pool for the “natural selection” of cancer cells by the physiological 
obstacles mentioned in chapter 2.1.2. (hallmarks 1-7). Only those cancer cells form a 
life-threatening metastatic cancer in the long run, which acquire enough drivers to 
overcome most of these obstacles and continue proliferating – this is a real evolutionary 
process. Unfortunately recent pharmacological therapies cannot exterminate 100% of 
cancer cells, there are always survivors. So drugs further stimulate this evolutionary 
process,52 selecting drug resistant cancer clones which eventually results in the relapse 
of the patient in most of the cases.53 
Vogelstein et al. defined 138 mut-driver genes according to mutation frequencies (54 
oncogenes and 71 tumour suppressors) which are responsible for the growth of most 
human cancers. A regular cancer accumulates 0-6 driver mutations during several years 
or even decades before the diagnosis.21 Besides, an average cancer harbours a huge 
number of passenger mutations, cancers from fast-renewing tissues the most (e.g. up to 
80000 in melanoma54).55 Actually, >99% of all genetic alterations detected in human 
cancers are merely passengers.21  
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While this model is clear and well-corroborated, it does not really address other genetic 
alterations than mutations (see points b), c) and d) in chapter 1.1.2.).56 For example, 
20% of all human cancers express malfunctioning proteins that regulate epigenetic 
modifications.57 Since epigenetic alterations are early phenomena in cancer58 their 
therapeutic reversal is very enticing.59 
The notion that huge percentage of cancers do not harbour unambiguous drivers led to 
the theory of mini-drivers. Instead of a few drivers with great impact, a multi-step, 
continuous model of cancer development has been proposed by Castro-Giner et al.60 
They say that many functions of a cancer cell are the result of numerous, redundant 
mini-drivers. Rather than occasionally gaining a major driver mutation, perpetual 
accumulation of mutations with modest effect provide the selective growth advantage 
eventually.61 
According to the concept of mutator mutations, the malfunction of DNA replication and 
damage repair machinery might be the primary alterations which rise the number of 
genetic alterations and drive cancer progression.62 Upon a selection pressure (like any 
anti-cancer drug) a possibly advantageous mutation arises sooner in cells with elevated 
mutation rate. The notion that cancers sometimes harbour the advantageous mutations, 
e.g. drug-resistant clones, already prior to therapy seems to corroborate this.63 This 
theory is based on the preconception that normal mutation rate in rapidly dividing cells 
is not enough to gather so many mutations. On the other hand, it is known that there are 
slow-dividing cancer cells.64 Furthermore, erroneous DNA damage repair increases CIN 
(which is a double-edged sword for cancer cells), so its therapeutic inhibition may be 
beneficial.65 
According to another aspect, a few MR (master regulator) proteins form small, 
autoregulated modules called cancer checkpoints.66  These checkpoints integrate the 
effect of heterogeneous genetic alterations (drivers) to a more defined cancerous cell 
homeostasis. Moreover, MRs themselves can malfunction due to post-translational 
modifications and drive cancer formation, indicating that rather protein abundance and 
activity data are needed instead of DNA mutation analysis to understand cancer 
function.67  
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These seemingly irreconcilable theories well represent that we have just began to 
untangle the roots of the most complex human disease. Nevertheless, the central role of 
genetic alterations seems to be fundamental in every model so far. 
1.2. Kinases 
1.2.1. Kinases as part of signal transduction pathways 
In living cells information flow is nothing more, but induced conformational alteration 
upon the physical interaction of molecules. Kinases are proteins with an enzymatic 
activity that are able to transfer a phosphoryl group (PO32-) from ATP to their substrates 
(lipids, carbohydrates or proteins).68 The phosphorylation reaction is highly substrate-
specific: in case of protein kinases, there is a consensus amino acid sequence in the 
protein substrate that should surround the phosphorylatable residue (a tyrosine, serine or 
threonine).69 This transfer then alters the conformation of the substrate protein and 
activates or impedes a specific function of it.70 Kinases are not active all the time – in 
fact they are mostly switched off. Furthermore the “on” and “off” states are non-binary, 
rather multi-step.71 The level of kinase activity might be influenced by phosphorylation 
(by another kinase or by themselves – later called autophosphorylation), or by binding a 
ligand molecule, a scaffold protein or another kinase domain of the same type.71 Finally, 
the effect of kinases is compensated by phosphatase enzymes which constantly remove 
the phosphoryl groups from the substrate molecules – so the conformation altering 
effect of kinases is mostly transient.72  
Every protein kinase has a similar conserved structural module – called domain – that 
possesses kinase activity: it consists of a smaller amino-terminal and a larger carboxy-
terminal lobe connected by a so called hinge. These two lobes form the MgATP-binding 
cleft (for ATP to coordinate its β and γ phosphate groups a Mg2+ ion is always needed) 
while the protein substrate bounds mainly to the carboxy-terminal lobe.71 Inside the 
amino-terminal lobe there is the αC helix – an important inner switch of activity – and 
inside the carboxy-terminal lobe there is the activation segment.73 The activation 
segment of the carboxy-terminal lobe has extended or closed conformation which is one 
factor influencing the activity of the kinase. It begins with a “DFG” motif – the 
aspartate residue D binds the crucial Mg2+ ion68– and its end interacts with the 
phosphorylatable serine / threonine / tyrosine residue of the substrate protein.74 There is 
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also a phosphorylatable residue in the activation segment, the phosphorylation of which 
is usually needed for enzyme activation.71 The exception is EGFR family kinases.75 
If the protein substrate of a kinase is also a kinase, a kinase cascade formed. Kinase 
cascades with multiple members are common types of signalling pathways. Signalling 
pathways are the means of signal transduction from receptors in the plasma membrane 
to transcription factors inside the nucleus.76 Signalling pathways amplify the signal up 
to a ~hundred fold77 and by cross-talking they form an elaborate information processing 
network inside every cell.78 In the end transcription factors regulate transcription of 
genes and the resulting proteins influence various cell functions: transcription of further 
genes and metabolism, growth, division, motility or apoptosis of cells.68  
Unprovoked increased activity of certain protein kinases – so corrupted information 
flow – is common in many human illnesses (diabetes, cardiovascular-, nervous- and 
inflammatory diseases and cancer) and their inhibition proved to efficiently mitigate the 
symptoms, so they have become the leading drug targets in the past two decades.79 
1.2.2. Kinases as drivers of cancers 
Given their central role in the regulation of so many cellular functions it is not 
surprising that many protein kinases are common drivers of cancers.80 As far back as 
1952 Williams-Ashman and Kennedy noticed that cancer cells usually more actively 
phosphorylate than healthy ones.81 Increased activity of a protein kinase overdrives the 
signal transduction pathway in which it is situated or – in case of the effector kinases – 
directly stimulates oncogenic cellular functions.82 Increased activity can be the result of 
a) various genetic alterations mentioned in chapter 1.1.2., b) increased paracrine or 
autocrine stimulation by ligands – in case of receptor-kinases, c) decreased phosphatase 
activity and d) increased structural stability due to elevated amount of chaperones (like 
HSP90).83 
The human genome encodes 538 protein kinases84 and of the 54 oncogenes in 
Vogelstein’s model 31 are protein kinases.21 Unfortunately, only mut-driver kinases or 
kinase fusion genes can be detected by DNA sequencing, the aforementioned other 
reasons of increased activity are by proteome analysis only.66 
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1.2.2.1. Aurora kinases 
Every cell is the result of a previous cell division. Cells that are not in a quiescent state 
(phase G0) continuously synthesize all their components and grow in volume (phase 
G1). During phase S also the DNA content (chromosomes) and the centrosome are 
duplicated. In phase G2 the cell continues to grow and prepares to the division itself, 
phase M (mitosis). The most delicate process in mitosis is the equal distribution of the 
duplicated chromosomes to the daughter cells (Figure 1). Centrosome contains 
centrioles and is the centrum of the microtubule scaffold system of cells.85 During 
mitosis microtubule spindles build up to connect the two centrosomes (polar 
microtubules) while some run to the cell membrane (astral microtubules) – these will 
excert the force that physically separates daughter cells. Other microtubule spindle 
fibers reach the pinch of the duplicated and condensed chromosomes – called 
centromeres – and join to the complex network of proteins there – called kinetochores.86 
When correctly aligned, these spindles pull sister chromatids evenly into distinct 
daughter cells.87 Ideally only one microtubule spindle should bind to one kinetochore 
and each sister chromatid to ones emanating from opposite centrosomes.88 Every other 
possibilities – if not corrected – cause aneuploidy, that is one form of CIN.89, 90 
Three cell cycle checkpoints – intricate systems of feedback signalling at important 
phase transitions – assess the condition of the cell and let continue cell cycle only when 
certain progresses are completed.91 They are the G1/S checkpoint, the G2/M or DNA 
damage checkpoint and the MC (mitotic checkpoint).92 The MC ensures equal 
distribution of chromosomes into daughter cells: since microtubule-kinetochore bonds 
created and break stochastically, the MC hinders sister chromatid segregation until all 
attachments are normal.93 
Aurora kinases are key effector kinases of cell division.94 They regulate maturation, 
duplication and separation of the centrosome, likewise proper mitotic spindle assembly 
and microtubule-chromosome attachment, furthermore separation of daughter cells –
cytokinesis – itself.95 
In humans the centrosome-associated Aurora kinase is denoted A, while the 
chromosome-associated paralogue B.96 
The third Aurora kinase ‘C’ orchestrates cell division of gametocytes.97 Aurora C has 
similar role to B98 and is overexpressed in several cancer cell lines.99 However, data 
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regarding its real significance in cancer is scarce, so it will not be discussed in this 
study. 
 
Figure 1. Scheme of a cell in metaphase. Duplicated chromosomes are arranged to the 
midsection of the dividing cell – called metaphase plate. Modification of picture from: 
[https://www.emedicalprep.com/study-material/biology/cell-structure-functions/cell-
cycle-cell-division] 
 
Aurora A 
The serine-threonine kinase Aurora A is expressed predominantly during mitosis in 
every human cell where it is localized at the centrosomes100 and transiently along the 
spindle microtubules.101  
Basically, function of Aurora A is regulated by expression and autophosphorylation but 
several other signals also impact its activity: hypoxic conditions102 or well-known driver 
kinases like PI3K (Phosphoinositide-3-kinase)103, BCR-ABL104 and HER2105 (human 
epidermal growth factor receptor 2) activate Aurora A kinase whereas Chrf106 and 
p53107 tumour suppressors promote its degradation. 
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The activation of Aurora A is a multi-step process, and besides (auto-)phosphorylation, 
it requires the interaction of protein TPX2.108 Activated Aurora A – directly or 
indirectly – stimulates all major intracellular signalling pathways: MAPK,109 
PI3K/Akt110 and NF-κB.111 However, the most important role of Aurora A is to 
facilitate the G2/M phase transition:112 it phosphorylates the aforementioned p53 
tumour suppressor113 and negatively regulates its function. In turn, p53 represses 
transcription of AURKA.114 Aurora A also phosphorylates the PLK kinase115 and 
activates key structure proteins that orchestrate maturation, duplication116 and separation 
of the centrosome.117 Later, during mitosis the main role of Aurora A is to stabilize 
microtubule spindles118 and indirectly to ensure the stabile biorientation of 
chromosomes.119 At the end of mitosis Aurora A also triggers the completion of M/G1 
transition, the “mitotic exit”.120 What is more, its degradation is crucial for the proper 
separation of daughter cells – called cytokinesis.121 
Role of Aurora A kinase in cancer 
Evidences point Aurora A as a biomarker of cancerous cell growth. The AURKA gene is 
located in a chromosome region that is frequently amplified in cancer.122 Indeed, 
besides AURKA gene amplification (that means Aurora A protein overexpression and so 
increased activity) transcriptional and posttranslational modifications all can increase 
Aurora A activity.123 Elevated Aurora A activity is a common phenomenon in several 
cancers like ones of the digestive tract,124 head and neck squamous cell carcinomas,125 
ovarian cancer,126 bladder cancer,127 cervical cancer128 and is associated with shorter 
cancer patient survival.  
Indeed, increased Aurora A activity influences many hallmarks of cancer formation: 
Hallmark 1), proliferation. Aurora A has some non-mitotic functions: it is able to 
phosphorylate important signalling proteins which relay proliferation signal.129 
Unfortunately cancer cells might express Aurora A in any phase130 in which case it 
fosters cell proliferation and induces resistance to cytotoxic therapy.131 
Hallmark 2), anti-apoptosis. Aurora A directly activates anti-apoptotic signalling111 and 
so confers resistance to many anti-cancer drugs.132 
Hallmark 3), genomic instability. As mentioned above, Aurora A facilitates cell phase 
transitions. Provided Aurora A has increased activity, it indirectly abrogates the G2/M 
DNA damage checkpoint.133 More importantly, increased Aurora A activity might result 
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in more than two centrosomes (and so multipolar spindles) and cytokinesis failure134 all 
of those leading to aneuploidy. This way Aurora A directly contributes to CIN and 
confers resistance to drugs which interfere with microtubule dynamics.135 
Hallmark 4) As a consequence of Aurora A activity VEGF expression is upregulated 
and angiogenesis is stimulated in the tumour mass.136 
Hallmark 5) Aurora A promotes EMT as well,105 through activation of several proto-
oncogenes like AKT,137 MAPK (mitogen-activated protein kinase),138 Coffilin-F-
actin,103 Src,139, 140 FAK (focal adhesion kinase),140 Rap-1A141 and NM23-H1.142 Aurora 
A-induced PI3K/Akt signalling also confers resistance to many cytotoxic drugs.132 
While overexpressed Aurora A protein causes multipolar spindles, cytokinesis failure, 
thus chromosomal aberrations, its transcriptional silencing impairs centrosome 
maturation and separation, leading to monopolar spindles, delayed mitotic entry,143 
activation of the MC and thus inhibition of cell proliferation. Silencing of Aurora A 
induced apoptosis in some experiments,144 it is still not clear whether Aurora A is a 
bona fide driver.134 However, since inhibition of Aurora A kinase activity hinders cell 
division it might be a useful therapeutic target in cancer.145 
 
Aurora B 
After the discovery of Aurora A, a paralogue serine-threonine kinase was identified in 
many organisms attached to the condensed chromosomes.146 The new kinase, Aurora B, 
is also activated by autophosphorylation and regulated by a complex network:147 for 
example BubR1,148 or Mad2 – if overexpressed149– counteracts Aurora B function while 
Bub1150 and the MAPK pathway151 activates Aurora B. 
Together with proteins INCENP (inner centromere protein),152 Survivin and Borealin,153 
Aurora B constitutes the highly important CPC (chromosomal passenger complex).147 
The CPC is located at the kinetochores during the first part of mitosis, and then 
relocates to the microtubule spindle during the last steps.154 The CPC ensures three 
delicate tasks during mitosis: 
1) condensation of the chromosomes through phosphorylation of histone H3 by Aurora 
B155, 156 
2) correct sister chromatid segregation.157 Aurora B phosphorylates the KMN (Knl1 - 
Mis12 - Ndc80) protein network, that part of the kinetochore which directly connects to 
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microtubules.158, 159 Phosphorylation destabilizes and breaks up erroneous microtubule-
chromosome connections which are always weaker than correct ones.160 On the freed 
kinetochores new, stabile attachments can build up and in the end only functional 
connections remain (each sister chromatid is connected to only one of the two 
centrosomes) that ensures equal segregation of chromosomes. This way Aurora B is an 
important constituent of the MC.161 Furthermore, Aurora B directly facilitates MC and 
chromosome segregation through activation of Mps1 kinase162 and Hec1 protein,163 as 
well. 
3) Cytokinesis. As the dividing cell is pulled apart by bipolar microtubule spindles, 
tension increases on kinetochores of bioriented chromosomes that separate CPC and 
thus Aurora B from there.164 The CPC then migrates to the half-section of the 
microtubule spindle – called midzone – and concerts cytokinesis.165 Assembly of the 
midzone protein complex on the microtubule spindle will mark the point where 
cytokinesis will occur.166, 167 At the end of mitosis Aurora B protein is degraded just 
like Aurora A.168 
Role of Aurora B kinase in cancer 
Currently no mutation is known in any genes of the CPC proteins. AURKB gene 
amplification, or altered promoter methylation have not been reported either.169 In 
human cancer cells level of Aurora B protein is often reduced, e.g. by simultaneous 
deletion of AURKB and TP53 genes.170 Since p53protein is able to arrest cell-cycle at 
the G2/M checkpoint in case of genetic alterations, absence of these two central 
regulator proteins might contribute CIN.171 The apoptotic regulator Mad2 protein – if 
overexpressed – also able to reduce level of Aurora B protein.149 
While reduced level of Aurora B is not linked to carcinogenesis, overexpression in 
many cancer cell lines and cancer types172 is explicitly associated with aneuploidy173 
and poor prognosis.174 The reason is that overexpression means increased Aurora B 
activity, over-phosphorylation the aforementioned KMN network and histone H3.173 
These false signals give rise to CIN through three mechanisms: a) accumulation of 
impaired microtubule-kinetochore connections leads to chromosome segregation 
problems and aneuploidy;175 b) cytokinesis failure gives rise to monstrous, 
multinucleated cells with amplified centrosomes which leads to mal-attachments in the 
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next mitosis and fosters aneuploidy even further;90 c) premature sister chromatid 
separation – that is poorly understood yet.176 
It is possible though, that in many experiments the elevated level of Aurora B might 
have been rather the result of increased proliferation itself, since it is predominantly 
expressed during phase G2 and mitosis.100 Also, Aurora B is overexpressed together 
with many other proteins regulating cell division – so it is not entirely clear yet, to what 
extent increased Aurora B activity contributes to CIN.169 Although loss of INCENP, 
Borealin and Survivin also impairs error correction and cytokinesis, there is no strong 
evidence that omission of any CPC components indeed increase segregation errors in 
mouse models.177 Nevertheless, if overexpressed Aurora B is only an accompanyment 
phenomenon, it is still an important one because druggable by KIs (kinase inhibitors –
see chapter 1.3.4.) – unlike Survivin or Borealin. 
It is worth to note that loss of Aurora B function results in very similar phenomena to 
increased activity178 and can be also detrimental to cells,179 so there is an optimal level 
of increased Aurora B activity (see also point 3 in chapter 1.1.2.).34, 175 Therefore it was 
hypothesised that further increasing the number of missegregations in cancer cell might 
be therapeutically favourable, but hard to carry out.180 On the other hand, depletion of 
Aurora B protein or inhibition of its kinase activity prevents cytokinesis, results in 
multi-nucleated polyploid cells and ultimately leads to apoptosis of normal and 
cancerous cells. Since kinase activity of Aurora B can be inhibited by designed small-
molecules, it qualifies as a potential drug target in cancer.181, 182 
Still, it is not clear whether increased Aurora B activity is a cause or a 
consequence183, 170 – many claim that Aurora A is the better target.184, 185 Indeed, while 
Aurora A is overexpressed in rapidly proliferating glioblastoma186 and breast187 cancer 
cells and correlated with poor outcome, B is not. Furthermore, inhibition of Aurora B 
caused neutropenia in some clinical trials.188  
Yet, since perpetual proliferation is the very essence of cancer and the number of 
druggable (see chapter 1.3.3.) proteins regulating it is limited, pharmacological 
inhibition of both Auroras remains a possible approach.189, 190  
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1.2.2.2. EGFR 
EGFR was the first RTK discovered,191 and is also one of the most studied kinase.192 It 
makes up the EGFR family with HER2, HER3 and HER4.193 The constitution of EGFR 
follows the standard build of RTKs (receptor tyrosine kinases): extracellular domains 
bind the ligand (receptor part) and facilitate dimerization. Linked to them through a 
short transmembrane segment the intracellular tyrosine kinase domain activates 
downstream proteins.194  
EGFR exists as an inactive monomer in the cell membrane of most epithelial cells194 
and activated when its extracellular domains bind one of its specific ligands e.g. EGF 
(epidermal growth factor).195 Two activated receptor monomers then able to form a 
dimer – called homodimer if two EGFRs, or heterodimers if different members of the 
EGFR family constitute it.196 Upon dimerization the two intracellular kinase domains 
get into proximity and form an asymmetric dimer, in which one kinase domain is the 
allosteric activator of the other.197 The activated kinase domain then phosphorylates the 
C-terminal cytoplasmic tail of its own (autophosphorylation) and of the other receptor’s 
(transphosphorylation) on several tyrosine residues.198 
Activated EGFR dimers internalized by endocytosis and either degraded or recycled.199 
However, simultaneously a signalling platform builds up on the phosphorylated 
C-terminal tails200 that serve as an origo for many signalling pathways201 encompassing 
circa 122 proteins:  
a) the RAS-RAF-MEK-ERK (also called MAPK) pathway,202, 203 
b) the PI3K-AKT-mTOR cascade,204 
c) the PLC-γ1-PKC pathway,205 
d) the Jak-STAT pathway,206 
e) and the NOTCH pathway.207 
Eventually most signalling pathway activates transcription factors that effectuate the 
signal coming from EGFR.196 This way EGFR is able to positively regulate most 
cellular processes: metabolism, growth, motility, differentiation, survival (anti-
apoptosis), migration (EMT) and angiogenesis.208, 209  Nevertheless, the most striking 
effect of EGFR activity is the one on proliferation: it drives cells past the G1/S 
checkpoint during cell cycle.210 But how can a single receptor regulate so many 
pathways? First, different ligands of EGFR211 and the different pH of the internalised 
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vesicules212 both seem to trigger distinct downstream pathways.213 However, the main 
source of this diversity is heterodimerisation.214 EGFR family members are able to form 
heterodimers also with other RTKs, such as c-Met. It is worth to note though that vast 
majority of these observations happened in cancer cells with overexpressed RTKs,215 
for example EGFR–c-Met heterodimers are present in hepatoma (liver cancer) cells but 
not in normal hepatocytes.216  
Furthermore, under certain stimuli EGFR can translocate to the nucleus where it 
phosphorylates nuclear proteins like histone H4217 and directly associates with 
transcription factors218 and activates genes like AURKA.219 The effect of these functions 
is also enhanced cell proliferation.220 
Role of EGFR in cancer 
The first relationship of receptor overexpression and cancer formation was 
demonstrated with EGFR221 so EGFR is also one of the first proven drivers. Indeed, 
active EGFR promotes many processes, all favourable for cancer cells (see hallmarks in 
chapter 1.1.2.): 
Hallmark 1) fosters continuous cell division,222 
Hallmark 2) promotes cell survival,223 
Hallmark 4) elevates the expression level of angiogenic factors and receptors,224 
Hallmark 5) induces EMT which triggers metastasis but also confers resistance to 
EGFR TKIs (tyrosine kinase inhibitors – see chapter 1.3.4.2.).225  
Of course, EGFR and the activated pathways also increase EGFR TKI drug resistance 
of cancer cells without activation of the EMT process.226, 227 E.g. heterodimerisation 
fosters TKI resistance, because a TKI-inhibited EGFR kinase domain is still able to act 
as an allosteric activator for c-Met.228 Another possible mechanism of EGFR TKI 
resistance is the increase of the activity of another signalling component that drives the 
same pathways as EGFR, like KRAS.229 In case of NSCLC (non-small cell lung cancer) 
the appearance of RTK c-Met can be such a phenomenon. Nuclear localisation of EGFR 
is also particularly common in cancer230 where it confers resistance to radio-, 
cytotoxic 231 and EGFR TKI therapy.232  
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Increased activity of EGFR can have many origins: 
1) Ligands of EGFR are often overexpressed in human cancers, most prominently EGF 
that triggers increased EGFR activity.233 Then elevated EGFR activity further facilitates 
EGFR expression in a positive feedback loop.234 
2) Methylation of the EGFR gene promoter increases translation and EGFR protein 
overexpression.235, 236 
3) The EGFR gene is often amplificated (that leads to protein overexpression and 
increased activity)237, 238 or mutated.239 These mutations stabilize ligand-independent 
homo/heterodimers,208 facilitate evasion of endocytosis (and the frequency of 
degradation, so “switching off” of the receptor),240 or constitutively activate the kinase 
domain itself. The EGFR kinase domain mutations can be classified into activating and 
resistance mutations according their main impact on the cancer cell. Activating EGFR 
mutations (e.g. point mutation L858R or various deletions right before the αC helix 
(EGFRDel)) increase and sustain phosphorylation (thus activity) of the receptor without 
ligand stimulation.241 This way the cancer cell becomes addicted to the activity of 
EGFR but simultaneously more sensitive to EGFR TKIs. Therefore these mutations are 
also called sensitising mutations and their presence and inhibition greatly improves 
patient survival.242, 243 Unfortunately, cancer becomes resistant in time and most 
patients relapse. Among the various reasons244, 245 new, secondary EGFR mutations are 
often the cause,246 like T790M residue exchange (see chapter 1.3.4.2.) that does not 
reduces the affinity of EGFR to the TKI but enhances its catalytic activity.247 The 
T790M accounts for approximately half of all secondary, resistance mutations.248 
Unfortunately the T790M mutation is sometimes present in the cancer before treatment; 
moreover it can also be an inherited polymorphism.19 
According to all these notions EGFR qualifies as a proto-oncogene249 in vitro250 and in 
many human cancer histotypes: carcinomas,251 sarcomas,252 gliomas253 and non-small 
cell lung cancer NSCLC.254  
1.2.2.3. c-Met 
C-Met is a RTK similar to EGFR and also situated in the plasma membrane. C-Met has 
one exclusive ligand, HGF (hepatocyte growth factor).255 When two c-Met monomers 
bind one HGF with their extracellular domains, they form a dimer and the intracellular 
kinase domains phosphorylate the C-terminal tails of each other.256 The active c-Met 
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(hetero- or homo-) dimer then activates signal transduction pathways, many common 
ones with EGFR.257 
Whereas in adults c-Met is expressed by many tissue types (e.g. liver, pancreas, 
prostate, kidney), its function is more vital during embryonic development and wound 
healing where it drives cell migration and normal EMT process.258 
Role of c-Met in cancer 
Increased c-Met activity can be a result of stronger-than normal autocrine / paracrine 
HGF stimulus or c-Met protein overexpression – latter sometimes due to MET gene 
amplification259– and is present in many cancer types with poor prognosis.260 Selective 
inhibition of c-Met is able to beat some cancer cell lines, and MET amplificated gastric 
or NSCLC patients respond to the c-Met–ALK dual inhibitor crizotinib. So in these 
examples c-Met seems to function as a driver.261 However, it is hard to appropriately 
select patients for c-Met targeted therapy262 because activity of other RTKs (e.g. EGFR) 
are usually also increased257 and they are able to form heterodimers. In other words 
increased c-Met activity is rarely a standalone phenomenon.256 Furthermore, activating 
mutations of c-Met are rare.263 
It is rather important that increased c-Met activity is a source of secondary resistance to 
EGFR TKIs264 and cytotoxic drugs,265 most of all in NSCLC.266 Similarly to resistance 
mutations of EGFR, erroneous presence and increased activity of c-Met sometimes 
occur before EGFR TKI treatment.267 In both of those cases, simultaneous inhibition of 
c-Met and EGFR restores sensitivity to EGFR TKIs in vitro.268, 269 This topic is still 
hot,270 since after a while cancer cell lines become resistant to c-Met inhibitors as well -
which foreshadows the clinical fate of c-Met inhibitor drugs.271, 272 
1.3. Targeted cancer therapy 
1.3.1. Types of targeted agents 
Surgery is the most obvious and also the oldest approach to cure cancer. It proves to be 
remarkably effective in case of some types of cancer, but has its limitations.273 In the 
past ~50 years conventional cytotoxic and radiotherapy have emerged and still represent 
an important force of anti-cancer efforts.274 Their common mechanism of action is to 
interrupt the division process at some point that induces apoptosis of the affected cells. 
Applied systemically, cytotoxic therapies act on every dividing cell – regardless they 
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are healthy or cancerous.275 Therefore most of their side-effects are derived from the 
malfunction of fast-dividing tissues and are quite harsh: skin rush, hair loss, digestion 
problems, immunosuppression, myelosuppression, mucositis and hepatotoxicity.276 
Unfortunately even this rude, generic intervention can’t keep cancer from acquiring 
resistance277 through various means e.g. overexpressing transporters that expel the 
cytotoxic drug.278 This principal problem facilitated the development of further 
alternatives: hormone,279 immuno-,280 gene281 and targeted therapy. 
Targeted therapies are designed to interfere with the very driver oncogene(s) of the 
given cancer type, patient, or single tumour itself. Of course healthy cells are also 
affected since they harbour proto-oncogenes but they are not “addicted” to them and 
therefore less sensitive to their loss – as coined by Weinstein et al.282 Unfortunately, 
resistance occurs with targeted agents as well283 and they not necessarily increase 
survival much better than cytotoxic drugs.284 Furthermore the number of available 
approved drugs is very limited even against proven drivers. It is also important to note 
that targeted therapies are useless without equally developed diagnostic tools, since only 
those patients benefit from a targeted agent who harbour the given oncogene.285 Four 
types of targeted agents exist up to day: monoclonal antibodies,286 aptamers,287 
immunotoxines288 and small molecule inhibitors. Regarding the topic of this Thesis the 
fourth type will be specified in the followings.  
1.3.2. Properties of small molecule KIs 
So called small molecule inhibitors are low molecular weight organic compounds that 
typically contain several heterocycles. They are not easily biodegradable, so can 
maintain an effective serum concentration for longer periods. Contrary to monoclonal 
antibodies which exclusively bind to extracellular domains of transmembrane proteins, 
small molecule inhibitors freely diffuse through cell membranes without active 
transport and can inhibit intracellular targets as well. The drawback of this is that small 
molecules are not targeted by themselves. That is, they can reach almost every protein 
in the body so inhibit their target no matter it is in a healthy cell or a cancerous one. 
However, they can be conjugated to targeting moieties like GnRH (gonadotropin-
releasing hormone),289 carbon nanotubes290 or embedded into liposomes291 to direct 
their spatial distribution in the body. 
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Most small molecules are developed to inhibit protein kinases because they are often 
drivers in cancers and relatively easily druggable (see chapter 1.3.3.) by structural 
analogues of ATP.292 Unfortunately many of the driver proteins e.g. most convergent 
nodes of pathways are transcription factors with no enzyme activity to inhibit.293 While 
the most widely used targeted agents against kinases are monoclonal antibodies, small 
molecule KIs are close second.294 
Since ATP is a highly conserved energy currency of all living things, it came as a 
surprise that analogues of ATP can have enzyme specificity at all. Indeed, the ATP-
binding pocket of protein kinases is highly conserved, but the surrounding (mostly 
hydrophobic) side-pockets are quite unique to the particular enzyme that enables 
remarkable selectivity of ATP analogue small molecule KIs.295 
When small molecule KIs attach to the surface of the target protein they disturb 
conformation of the enzyme and block its activity. This can be achieved through several 
ways.73 Basically, KIs are classificated according to the activation state of the kinase 
target they bind: 
Type I and II inhibitors are ATP competitive. They all reversibly occupy the ATP-
binding pocket thus have to compete with high intracellular ATP concentration. They 
prefer different positions of the αC helix and DGF sequence – so active (DFG-in) or 
inactive (DFG-out) conformations, respectively – and utilize the back/front hydrophobic 
side-pockets depending on their type. Type I inhibitors bind without regard to the 
conformation of the kinase, but might induce either DFG-in or -out states. Whereas type 
II inhibitors specifically recognise the DFG-out state. Examples of Type I or II 
inhibitors are VX-680, MLN8054, MLN8237, erlotinib and crizotinib.296 
Type III allosteric inhibitors occupy a pocket close to the ATP-binding pocket -thus 
they are uncompetitive or noncompetitive inhibitors of ATP.297 
Type IV allosteric inhibitors occupy a pocket far from the ATP-binding pocket. 
Type V inhibitors are bivalent inhibitors because they are able to bind to two different 
regions of the protein kinase domain at the same time.298 
Type VI inhibitors are irreversible: they occupy the ATP-binding pocket like type I 
inhibitors but harbour a reactive moiety that binds covalently to a suitable residue of the 
kinase. This way the targeted kinase protein becomes permanently disabled.299 
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Protein KIs usually bind to their target enzyme by forming 1-3 hydrogen bonds with the 
hinge residues and also interacting with residues of the ATP-binding site and the 
hydrophobic pockets. A significant amino acid residue of the ATP-binding site is the 
gatekeeper residue (e.g. threonine 790 in case of EGFR) that usually shrinks a 
hydrophobic pocket and hinders the attachment of KIs.300 The effectiveness of a 
reversible inhibitor can be described with the dissociation constant and the IC50 value – 
later is the inhibitor concentration required to elicit half of the maximum effect. 
The number of diseases targeted by KIs is increasing: inflammatory and autoimmune 
diseases,301 hypertension, Parkinson’s disease. However, most KIs are designed 
purposely for cancer treatment.302   
Protein KIs have generally good toxicity profile303 but some patients experience quite 
harsh side-effects.304 Still, targeted agents do not prolong life greatly compared to 
conventional cytotoxic drugs.305 After the initial response306 resistance occurs to nearly 
all KIs in a few months or years. 
1.3.3. Development of small molecule KIs 
The two preconditions of anti-cancer drug development are:307 
- a validated drug target, practically a malfunctioning protein that is a proven driver of 
cancer. Furthermore, it has to be druggable – that is it has to be accessible by e.g. small 
molecule drugs and should have a specific function that can be inhibited upon binding 
with the drug. 
- finely adjusted, reliable assays that provide useable data. 
Provided these are given, the time-honoured first step of drug development is the 
screening of numerous compounds against the targeted kinase. Large molecule libraries 
contain several thousands of compounds and usually have a multi-layer structure – like 
the NCL™ (Nested Chemical Library™) of Vichem Ltd. (Figure 2). In case of focused 
or knowledge-based screening only a smaller subset of the molecule library is checked 
that is likely to have activity – like the EVL™ (Extended Validation Library™) of 
Vichem Ltd.308 There are of course more modern approaches to drug development, e.g. 
in-silico modelling and design is getting more and more invaluable. Except molecular 
docking none of them were used in the Thesis, therefore not discussed here. 
The tool of screening is mostly an in vitro assay where a recombinant kinase represents 
the target. This approach focuses only on the interaction of compound and kinase. 
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However, it is possible to utilize more expensive and time consuming cell-based assays 
on cell lines driven by the particular target. In that case some information is acquired 
also on the metabolism and secretion of the compound in a living cell.309 This is 
important because many compounds that effective in in vitro enzyme assay fail in 
cellular tests due to a number of conditions modifying their effect (e.g. enzymatic 
degradation or susceptibility to drug efflux pumps).310 However, in this case subsequent 
assays are even more important to confirm mechanism of action of compounds.311 
Whether enzyme or cell-based assays are the best to begin is still an open question.312 
Finally, the outputs of a screening process – called hits – have verified activity on the 
given target. Dose-response curves of hits usually obtained as soon as possible to get 
IC50 values which enable refined comparison of compounds. 
 
 
Figure 2. Build-up of the Nested Chemical Library (NCL™) of Vichem Ltd. 
[https://vichemchemie.com/nested-chemical-library-ncl] 
 
The second step of drug development is the hit to lead phase. Hits undergo many further 
functional assays to test their “drug-likeness”: pharmacokinetic properties like the 
aforementioned membrane permeability, and ADME (absorption, distribution, 
metabolism, excretion) parameters. Also solubility and drug selectivity measurements 
commenced in this phase. The aim of SAR (structure-activity relationship) study is to 
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define essential substituents associated with activity. Small molecules usually designed 
according to Lipinski’s rule of five313 and considered drug-like if they possess these 
features: 
- have molecular weights of less than 500 Dalton (g/mol) 
- have a clogP value (a measure of membrane permeability) not greater than 5. 
- have no more than 5 hydrogen bond donors 
- have a maximum of 10 hydrogen bond acceptors 
Promising molecules are addressed to the next step: lead optimization. During this 
phase the aim is to maintain favourable properties while improving deficiencies through 
modification of the structure. For this purpose new analogues are synthetized. After 
additional rounds of pharmacokinetic and in vivo pharmacodynamic assays, a clinical 
candidate is declared. 
 
Figure 3. Scheme of the drug discovery and development process. The diameter of the 
funnel represents the number of molecules involved at the particular level. 
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Up to 106 molecules have to be screened to find one or two clinical candidates. Attrition 
of compounds in the clinical phases is much lower – approximately 1 in 10 reaches the 
market. In turn, the cost of clinical trials is much higher than of the previous preclinical 
tests (Figure 3). 
1.3.4. Examples for small molecule KIs 
1.3.4.1. Aurora KIs 
Inhibition of Aurora kinases affects all dividing cells like conventional cytotoxic drugs 
therefore similar systemic effects are expected. The rationale of aurora inhibition lies in 
the fact that their activity tends to be increased in cancer cells (see chapter 1.2.2.1.). 
AKIs (Aurora kinase inhibitors) can be more-or-less paralogue selective or pan-AKIs. 
The major cellular phenotypic response of dual Aurora A and B inhibitors is consistent 
with inhibition of Aurora B, in other words inhibition of Aurora B has dominant 
phenotype.314 So it was hypothesized for a long time that these dual inhibitors mediate 
their anti-cancer activity through inhibition of Aurora B activity.315, 316 Now there are 
quite selective Aurora A inhibitors that also able to induce apoptosis. The most notable 
AKIs that reached phase II up to date are: 
- VX-680 (tozasertib, MK-0457, Figure 4/A) is a type I small molecule inhibitor that 
promotes DFG-out conformation of Aurora kinases317 A and B – so it is a pan-AKI. 
VX-680 efficiently abrogated the growth of tumour xenografts in animal models318 but 
failed in clinical trial phase II due to frequent adverse events and low efficiacy.319 
- MLN8054 (Figure 4/B) and MLN8237320 (alisertib, Figure 4/C) are both type I 
inhibitors, promoting DFG-out state. Since Aurora A is more likely a driver, so MLN 
8054 was developed by Millennium Pharmaceuticals (now Takeda Oncology Company) 
in 2007 to be selective to Aurora A. MLN8054 decreases proliferation of cancer cell 
lines in in vitro cell culture and in xenografts.321 Unfortunately in phase I study 
MLN8054 caused somnolescence in patients with advanced solid cancers because of 
off-target GABAA receptor (GABAAR)-binding.322 After minimal modification of the 
structure of MLN8054 a new analogue, namely MLN8237 was developed. MLN8237 
has similar pharmacokinetic properties to MLN8054 and quite the same GABAAR-
binding but has increased affinity to Aurora A.320 Several clinical trials have been 
commenced with MLN8237 alone323, 324, 325 or in combination with other 
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drugs326, 327, 328, 325 but only one proceeded to phase III so far, and even that one was 
terminated in 2015329 because of harsh general cytotoxicity. However, applying it more 
carefully for the treatment of selected patients and using more precise dosing MLN8237 
is worth for further investigation.330, 331 So recently new trials have been started with 
MLN8237. [www.clinicaltrials.gov] 
Figure 4. Chemical structure of reference compounds A) VX-680, B) MLN8054 and  
C) MLN8237 
 
- AZD1152 (barasertib) is a dedicated Aurora B inhibitor which induces apoptosis in 
human ALL (acute lymphoblastic leukaemia)332 and AML (acute myeloid leukaemia)333 
cell lines. After several phase I studies AZD1152 was evaluated in two phase II trials 
with randomized AML patients. Despite frequent adverse events334 approximately 35% 
of patients had complete cancer remission compared to 11.5% in case of the 
conventional cytotoxic drug cytosine arabinoside.335 AZD1152 showed transient 
toxicity and modest response in ~20% of B-cell lymphoma patients, but further phases 
as monotherapy were not encouraged in the report.336 
- AT9283 (type I, promotes DFG-in) is rather a multi-kinase inhibitor with considerable 
effect on Aurora A/B, JAK2/3 and ABL1 kinases.337 After several phase I studies 
AT9283 failed in phase I/II trial due to lack of clinical response.338 
- ENMD-2076 (type I, promotes DGF-in) inhibits FLT3/4, RET, Aurora A and 
VEGFR3 kinases in the low nanomolar range. Unfortunately it failed in clinical phase II 
trial against ovarian clear cell carcinoma because of low efficiacy.339 However, ENMD-
2076 provided benefit for 17% of advanced or metastatic triple-negative breast cancer 
patients with moderate adverse effects.340 
DOI:10.14753/SE.2019.2277
29 
 
- PHA-739358 (danusertib, type I, promotes DGF-out) is basically also a pan-AKI with 
slightly stronger effect on Aurora B than Aurora A. Two phase II trials were performed 
with PHA-739358. In the first study toxicity was tolerable and ~13% of prostate cancer 
patients had complete remission after failing to respond to Docetaxel.341 In the second 
study patients with various types of cancer (including NSCLC) had manageable adverse 
effects but also minimal progression.342 Currently there is no sign of any new study with 
PHA-739358. 
- SU-6668 (orantinib) is a potent inhibitor of several kinases including Aurora A and 
B.343 Phase I/II study of SU-6668 for advanced hepatocellular carcinoma was completed 
with promising results344 but a phase III study in combination with transcatheter arterial 
chemoembolization in advanced hepatocellular carcinoma was terminated because the 
treatment did not improve overall survival of patients at all.345 
- MK-5108 is a highly selective Aurora A inhibitor (type I, promotes DGF-out). Despite 
modest effect in monotherapy, anti-cancer activity of MK-5108 was significantly 
enhanced when combined with taxane-based cytotoxic drugs in preclinical studies.346 
However, phase I study was terminated due to high toxicity when administered in 
combination with docetaxel.347 
To sum up, at least 30 AKIs have been evaluated as cancer therapeutics in the last few 
decades348, 349, 350, 351, 188 yet, there is still no approved AKI in the market. The possible 
reasons are diverse. For example one huge handicap of AKI therapy is the lack of 
markers (including Aurora A or B expression levels themselves) which significantly 
correlate with their anti-cancer activity.188 Therefore patients cannot be selected to AKI 
trials (about how important is to have selected patients for trials of targeted agents see 
next chapter on erlotinib and gefitinib). Furthermore, it might be possible that selective 
Aurora inhibition alone is not eligible for cancer monotherapy at all: 
1) Inhibiting cell division is a strategy very alike to conventional cytotoxic drugs. 
Although cancer cells are more susceptible to it, side-effects still common (see history 
of AKIs above). 
2) Preclinical experiments suggest that Aurora inhibition might induce cancer cell 
senescence, that would result in disease stabilization instead of remission.352 
3) Response to Aurora inhibitors is slow because certain cycle of cell divisions should 
occur beforehand (see also chapter 4, Figure 10).353 
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4) Interacting protein partners of Aurora kinases (TPX2 and INCENP) influence 
whether the kinase is in a DFG-in or -out state and so alter the paralogue selectivity and 
efficacy of AKIs accordingly.354 
There is also no multi-kinase inhibitor with strong effect on Aurora kinases which 
succeeded in clinical trials so far. However, many of the aforementioned studies suggest 
using AKIs in combination with conventional cytotoxic drugs.355 Since concurrent 
treatment with targeted agents is on the rise, also AKIs have already been combined 
with other small molecules (see 1.3.5.). 
1.3.4.2. EGFR inhibitors 
EGFR inhibitors were among the first targeted small molecule KIs designed and 
approved. The most notable examples are: 
- erlotinib (Genentech, approved by the FDA (food and drug administration of the US) 
in 2004) and gefitinib (AstraZeneca, FDA approved in 2003, withdrawn in 2005, 
approved again in 2015) were the first line of EGFR TKIs. Initial clinical trials of 
erlotinib and gefitinib were conducted on unselected patient cohorts therefore failed to 
show significant response.356 It turned out soon that they give longer survival compared 
to cytotoxic drugs only in patients harbouring certain activating EGFR mutations like 
EGFR L858R and EGFRDel),.242, 357 It later turned out to be a general phenomenon: 
various EGFR mutations have very different sensitivity to a given TKI.358 
Unfortunately, even among patients initially responding to erlotinib or gefitinib 
resistance occurs in time, resulting in a median overall survival of only 27 months.359 So 
second-generation EGFR TKIs were developed to overcome resistance mutation 
T790M – all of them are irreversible, class VI inhibitors: 
- afatinib has been the third FDA-approved EGFR TKI, it is active against both 
activating and resistance mutant EGFR.360 
- neratinib (HKI-272) is active against certain resistance EGFR mutations but not 
against common ones.361 In a phase II study neratinib in combination with temsirolimus 
(a cytotoxic drug) produced responses in ~19% of patients.362 Nertatinib has been 
approved for adjuvant therapy. [https://www.accessdata.fda.gov/scripts/cder/daf/index. 
cfm?event=overview.process&varApplNo=208051] 
- PF-00299804 (dacomitinib) is an experimental irreversible inhibitor of EGFR with 
which several phase III trials were conducted so far. One of them ended in 2017 and 
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found PF-00299804 a little bit more effective than gefitinib for NSCLC.  
[https://www.medpagetoday.com/MeetingCoverage/ASCO/65818] 
[http://www.medscape.com/viewarticle/881192)] 
The third generation of approved EGFR TKIs were also designed to inhibit activating 
and resistance mutations but without inhibiting wild-type EGFR: 
- osimertinib was approved in 2017 by the FDA.363 
- olmutinib is a type IV EGFR inhibitor approved only in South Korea.364 
- EGF816 (nazartinib) is still in experimental phase.365 
The new step of the never-ending race, a new secondary EGFR mutation (C797S) was 
found recently in one patient that restores resistance to osimertinib366, 367 and 
olmutinib.368 Strange enough, this mutation appeared to be sensitive to first-generation 
EGFR TKIs alone or in combination with a third-generation one.369  
While inhibitors of resistance mutant EGFR already exist, if MET gene amplification 
(and overexpression of c-Met) is diagnosed, patients have poor prospects. Therefore it is 
highly desirable to develop dual EGFR–c-Met inhibitors (like compound 34)370 or 
assess the feasibility of EGFR and c-Met inhibitor drugs in combination. 
1.3.4.3. c-Met inhibitors 
Inhibitors of c-Met are less numerous than AKIs or EGFR TKIs: 
- crizotinib. Up to date the ALK/ROS1 inhibitor Crizotinib (Pfizer, FDA-approved in 
2011) is the only marketed drug with significant potency on c-Met.371 Crizotinib was 
designed to be a selective c-Met inhibitor372 but was approved for the treatment of 
EML4-ALK fusion protein-driven NSCLCs (5% of all NSCLC patients). The overall 
response rate is 57% and resistance occurs with a median of ~10 months. A dozen of 
mutations can cause resistance to crizotinib but strikingly most of them don’t affect the 
sequence or abundance of EML4-ALK protein.373 
- BMS-777607 (Bistrol-Myers Squibb) is an effective inhibitor of c-Met, RON and 
AXL kinases.374 BMS-777607 proved to be effective against gastric cancer xenografts 
in vivo375 but failed in Phase I/II trials on patients with advanced or metastatic solid 
tumours [clinicaltrials.gov]. 
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1.3.5. Combinatorial therapy 
Conventional cytotoxic drugs of different mechanism of action were first designed for 
monotherapy, but it turned out soon (as far as 1960) that their combination boosts the 
anti-cancer effect in many cases.376 Similarly, first KIs (regarding the topic of the Thesis 
predominantly the combination of KIs will be discussed in the followings) were 
designed to be exclusively selective for the targeted kinase, but this task turned out to be 
difficult. Differences in the side pockets of the ATP-binding pocket are not so huge to 
allow designing a 100% selective inhibitor for any kinase. Therefore most current KIs 
have a more or less wide spectrum of targets.377 
Unfortunately, KI monotherapies often result in the resistance of cancer cells because 
they tend to harbour more than one driver at the moment of diagnosis and if not, they 
easily collect new ones when treated with drugs due to CIN.378 Thus, multi-target KIs 
would be rather desirable. However, due to the differences of side pockets it is almost 
impossible to design a multi-target, ATP-analogue KI for two (or more) arbitrary 
kinases. It is much easier in case of evolutionarily related kinases (like members of the 
EGFR family) than distant ones, (like EGFR and c-Met).370 Since driver kinases in a 
cancer cell seldom related in structure, this condition highly limits the use of multi-
kinase KIs as anti-cancer drugs. 
Another approach is to use KIs in combination. Theoretically any two or three kinases 
could be targeted this way, in fact toxicity frequently limits the applicability of 
otherwise successful combinations.53, 379 There are further reasons why combining 
targeted agents in general is more challenging than conventional cytotoxic drugs380: 
- their mechanism of action is more complex and thus not completely understood, 
- there is a lack of standardised preclinical and clinical tools to assess target effects, 
- conventional methodology of clinical trials might not be suitable for combination 
therapies, 
- regulatory and intellectual property circumstances are not favourable for the 
commercialisation of drug combinations, 
- finally, drug combinations are expected to have higher price for healthcare systems 
and patients.381 
So up till now there is no approved combination of targeted agents, they are typically 
applied together with traditional cytotoxic drugs.382 At the same time, results of clinical 
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trials are enticing because combination of targeted agents also have some compelling 
advantages:383, 384 
- existing drugs can be approved for several new indications as part of a combination, 
which also means more available new therapy. Considering that the growing expenses 
of development more and more delay approval of new drugs, it really is good news. 
- it is possible to assess the most effective (see synergism soon) drug cocktail on the 
given driver set. This approach – called personalised medicine – promises maximal 
therapeutic effect with minimal side-effect, 
- the most substantial property of combination therapy is that it can forego and 
overcome drug resistance by targeting multiple drivers306, 293 and multiple pathways.385 
It is worth to note that while occurrence of drivers – either prior to treatment or as 
secondary resistance – is heterogeneous, it has recurrent patterns that help to design 
effective drug combinations.293 Accordingly, the possible setups for combinatorial 
therapy might be (in case of two drivers): 
- inhibition of the same driver with two drugs – resistance easily emerge in this case.386 
- inhibition of multiple nodes in the same pathway – it is better because more than one 
driver in the same pathway is rare,387, 388 it rather occurs as drug-induced 
resistance.389, 390 
- inhibition of components of parallel signalling pathways which are typically utilized 
by cancer cells to bypass monotherapy, like c-Met amplification and overexpression 
upon EGFR TKI therapy,391, 392 or GPCR (G protein-coupled receptor) activation upon 
MAPK inhibition.393 
So called synthetic lethal interaction of certain protein targets offers an exceptionally 
favourable – albeit rare – opportunity for drug combinations. The term “synthetic 
lethality” means that inhibition of either protein causes no harm to cancer cells but both 
induce apoptosis. For example defect of a tumour suppressor (e.g. BRCA1 – breast 
cancer 1) endows another protein (e.g. PARP – poly (ADP-ribose) polymerase) to be 
essential for cancer cell survival and the concomitant inhibition of this second enzyme 
induces strong apoptosis.394 According to a recent study Aurora A kinase inhibition is 
synthetic lethal with loss of the RB1 tumour suppressor gene.395 Also EGFR and c-Met 
can act as synthetic lethal pairs in some circumstances.269 
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Several mathematical models exist to assess the effectivity of a given drug combination. 
The method of Chou and Talalay396 is the most widely used nowadays. According to 
this model a combination of two drugs (each one at an exact concentration) has a CI 
(combination index) value that indicates whether synergy, additive effect or antagonism 
arises at the given concentrations. Synergy is desirable, because it typically means high 
effect at low doses – so less drug burden for the patient (and presumably less severe 
side effects). 
Last, but not least it is crucial to know the individual drivers present in the given cancer 
before commencing combinatorial therapy. Sometimes even the combination of 2-3 
drugs to block 2-5 pathways are needed to kill all cancer cells in cellular experiments. 
On the other hand, some of these combinations work at extraordinarily low doses (but 
still at low CI values) – as it was observed in promising in-house experiments (data not 
shown). Whether these results will apply to more complex in vivo systems is of course 
yet to decide. 
Also AKIs have already been combined with many targeted agents. For the scope of the 
Thesis the following combination partners are particularly important: 
- EGFR inhibitors397 
- Src inhibitiors,398, 399 
- PI3K/mTOR pathway inhibitors400 
- histone deacetylase inhibitors.401, 402 
- farnesyl transferase inhibitors403 
- proteasome inhibitors [https://clinicaltrials.gov] 
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2. Aims of the Thesis 
 
The general aim of my work was to progress the field of targeted drug development. 
Considering the central role of Aurora kinases in cell division and cancer, the lack of 
approved AKIs is perplexing. In the molecule library of Vichem Ltd. a small molecule 
family was found to have promising effect on Aurora kinases. The compounds are 
based on a benzotiophene-3-carboxamide scaffold, unprecedented among published 
AKIs. Therefore in the followings I had one major and two secondary objectives: 
 
I) To corroborate the AKI potency of the benzotiophene-3-carboxamide derivatives. To 
achieve this, biochemical (in vitro enzyme assays), computational (in silico molecular 
docking) and various cellular assays (cell viability measurement, flow cytometry, 
fluorescence microscopy and western blot) were utilized. In the end a lead molecule was 
selected. 
 
II) To achieve better understanding of Aurora kinase inhibition using the 
benzotiophene-3-carboxamide derivatives. Therefore structure-activity relationship 
(SAR) and Aurora paralogue selectivity of the compounds were monitored. 
 
III) To test the lead AKI compound in combination with experimental or approved 
targeted agents. Six of the applied combinations were already published, one was an 
original idea and one was performed by using another in-house inhibitor. 
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3. Materials & Methods 
 
Compounds 
The benzotiophene-3-carboxamide based AKIs (compound 1-33) and the EGFR–c-Met 
dual inhibitor (compound 34) were designed, synthesised and provided by the Vichem 
Chemie Ltd. (Budapest, Hungary). The reference compounds VX-680, MLN8054, 
erlotinib, crizotinib were purchased from Selleck Chemicals LLC (USA) and Sigma-
Aldrich, respectively. All compounds were solved in anhydrous DMSO (dimethyl 
sulfoxide), stored at rt (room temperature) and their purity was verified by HPLC every 
three months. 
The Molecular Library of Vichem Ltd. possesses more than 17000 chemical entities 
collected around 110 core structures, majority of them original, patentable compounds. 
The EVL™ encompasses ~2000 carefully chosen compounds as a representative set of 
the whole Molecule Library. 
 
General cell culturing protocol and cancer cell lines 
HCT 116 and HT-29 human colon carcinoma cell lines were obtained from ATCC 
(American Type Culture Collection, Rockville, MD, U.S.A.), primer fibroblast cells 
were isolated in-house. HCT 116 was maintained in McCoy’s 5A, HT-29 in RPMI and 
primer fibroblasts in DMEM cell culture medium supplemented with 10% (V/V) FBS 
(foetal bovine serum). All media contained antibiotics (MycoZap™ Plus-CL, Lonza 
Group Ltd., Switzerland). All cell lines were cultured at 37°C, in a humidified, 5% CO2 
incubator. Cell culture media containing FBS and antibiotics are referred as “complete 
media”. 
Routine passaging and seeding to multi-well plates for experiments was performed with 
typsinisation: cell culture was washed with sterile PBS (phosphate-buffered saline), then 
incubated with 0.1% trypsine-EDTA solution (Lonza) for 10-15 min at 37°C, in a 
humidified, 5% CO2 incubator. Detached cells were resuspended with excess amount of 
complete medium and pelleted by centrifugation (300x g, rt). The pellet was 
resuspended in 1 ml complete medium and 50 μl of it was mixed with equal amount of 
0.4% (m/V) trypan-blue solution. Cell number in the stained sample was counted with 
Bürker-chamber. 
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MTT cell viability assay 
For MTT measurements 8000 cells were seeded into each well of a 96-well plate in 
150 μl complete medium. Cells were let to attach overnight at 37°C in a humidified, 5% 
CO2 incubator. Four-fold concentrated dilutions of drugs were added to the wells – each 
in 50 μl. The concentration of DMSO was always kept at maximum 0.5% (V/V). For 
the determination of IC50 values three-fold serial dilutions were created starting from 
10 µM. After further 48 h incubation the treatment medium was removed and 50 μl 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (2 mg/ml 
in PBS) was added to each well. Plates were incubated (1.5 h, 37°C), MTT solution was 
carefully removed and crystalline formazan was solubilized with 200 μl detection 
solution (2-propanol, 1 mM HCl and 10% (V/V) Triton X-100). Absorbance was 
measured with a Synergy 2 plate reader (BioTek), at wavelengths 570 and 635 nm. The 
635 nm data (reference wavelength) was subtracted from 570 nm data (test wavelength) 
and results were used to calculate normalised cell viability data compared to DMSO 
treated positive and cell-free negative control wells. Using these data IC50 values were 
determinated with Excel (Microsoft) and XLfit 5.1.0 (IDBS, Surrey, UK) software. 
 
In vitro inhibition of recombinant kinase activity 
Active, recombinant Aurora A and B enzymes were incubated with ATP, fluorescent 
dye-conjugated peptide substrate and compounds of various concentrations in a suitable 
buffer solution. 
Constitution of Aurora A reaction buffer was: 20 mM HEPES (4-(2-hydroxyethyl)-1-
piperazine-1-ethanesulfonic acid) pH 7.5, 1 mM DTT (dithiothreitol), 2 mM MgCl2 and 
0.01% (V/V) TWEEN 20 as detergent. TAMRA-PKAtide (5TAMRA-GRTGRRNSI-
NH2, Sigma) was used as substrate at a final concentration of 400 nM. The final 
concentration of ATP was 8.3 µM (KM[ATP]) and 8 nM for the Aurora A recombinant 
kinase (Proteros Biostructures). 
Constitution of Aurora B reaction buffer was: 20 mM HEPES pH 8.5, 1 mM DTT, 
2 mM MgCl2 and 0.01% (V/V) BriJ35 as detergent. TAMRA-PKAtide (5TAMRA-
GRTGRRNSI-NH2, Sigma) was used as substrate at a final concentration of 400 nM. 
The final ATP concentration was 125 µM (KM[ATP] for Aurora B). Aurora B 
recombinant kinase (SignalChem, lot: E021-1) concentration was 4 nM. 
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Enzyme activity was assayed in 384 well microtiter plates (Corning 3676). Reaction 
time was 30 min for Aurora A and 1 h for Aurora B, at rt. Arrest of enzyme reaction and 
detection of the phosphorylated peptide substrate was performed by IMAP detection 
mixture (100% (V/V) IMAP Binding Buffer A, 1/400 IMAP Binding reagent, 
Molecular Devices). The fundament of IMAP assay is that phosphorylated peptides 
bind with high affinity to metal ions (M3+) immobilized on the surface of nano-scale 
beads. The phosphorylated peptide substrates are conjugated with fluorophores (like 
5TAMRA – carboxytetramethylrhodamine). Upon binding to the bead the degrees of 
freedom of the peptide and the fluorophore decreases and do not spoil polarisation of 
the illuminating fluorescent light (Figure 5). Fluorescence polarization and fluorescence 
intensity measurements were performed using an Analyst GT Multimode Reader 
(Molecular Devices). Quantification of enzyme activity values was done compared to 
positive and negative controls. Preliminary screens were run at 10 µM [ATP]. For IC50 
determination the KM[ATP] (Michaelis-Menten constant) values were determined for both 
enzymes and enzyme reactions were run at the calculated [ATP] – see exact values 
above. Determination of IC50 values were made with Excel (Microsoft) and XLfit 5.1.0 
(IDBS, Surrey, UK) software. 
 
Figure 5. Scheme of IMAP technology. 
[http://www.moleculardevices.com/pages/reagents/imap_intro.html] 
 
Flow cytometry methods 
For both staining methods cancer cells were seeded into 24 well plates and let to attach 
overnight at 37°C, in a humidified, 5% CO2 incubator. Next day culture medium was 
changed to medium containing reference and in-house compounds and cells were 
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treated at the concentration and for the time indicated, respectively. After treatment 
supernatants were collected together with trypsinized cells. The proportion of 
fluorescent cell populations was detected with a FACSCalibur flow cytometer using 
CellQuest Pro software (BD Biosciences). Sample evaluation was performed also with 
CellQuest Pro and Excel (Microsoft) software. 
- PI (propidium-iodide) staining 
Cell suspensions were centrifuged (250x g, 4 min, 4°C) and fixed with ethanol (70%, 
-20°C). After at least 24 h (but never more than 72 h) cells were pelleted (250x g, 4 min, 
4°C), resuspended in 300 µl apoptosis buffer (200 mM Na2HPO4, 200 mM citric acid 
pH 7.8) containing 100 μg/ml RNase A (Sigma), incubated (30 min, rt) and 
supplemented with PI at 10 μg/ml final concentration. After additional 5 minutes of 
incubation samples were run on the flow cytometer. 
- PI staining and Annexin V labelling 
Trypsinized cell suspensions were centrifuged (200 x g, 10 min, rt) and washed once 
with great volume of PBS. Cell pellets were incubated with 100 µl PBS containing 
Annexin V-FLUOS conjugate (20 min, rt, dark) at the recommended concentration 
(ROCHE, Ref.: 11 828 681 001). After staining, cells were pelleted again (250 x g, 4 
min, 4°C) and resuspended in 300 μl PBS containing PI at 10 μg/ml final concentration. 
After additional 5 minutes of incubation samples were run through the flow cytometer. 
 
SDS-PAGE and western blot analysis  
Cancer cells were seeded into 60 mm Petri dishes in complete medium and let to grow 
until 90% confluency. Then media were changed to fresh complete media with 
indicated compound concentrations. Cells were incubated with the compounds for 3 h 
(37°C in a humidified, 5% CO2 incubator) then washed with PBS and lysed at 4°C with 
ice-cold RIPA buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1% (V/V) NP-40, 0.5% 
(V/V) sodium deoxycholate, 0.1% (V/V) SDS, 2 mM EDTA, 2 mM EGTA, 
supplemented right before use with 1 mM DTT, 1 mM sodium orthovanadate, 200 µM 
PMSF (phenylmethylsulfonyl fluoride) and 0.5% (V/V) protease inhibitor cocktail 
(Calbiochem). Cell lysates were scraped with rubber policeman, pipetted into Eppendorf 
tubes, sonicated for 4 x 10 seconds and incubated in ice for additional 20 minutes. 
Lysates were centrifuged (10000x g, 15 min, 4°C) and protein concentration of the 
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supernatants were determined according to Bradford method (#500-0207 Bio-Rad). 
Finally, lysates were mixed with loading buffer (5x concentrated, 62.5 mM Tris-HCl pH 
6.8, 2% (m/V) SDS, 10% (V/V) glycerol, 50 mM DTT, 0.01% (m/V) bromophenol 
blue) and denatured by boiling (5 min, 100°C). Sample volumes containing 4-80 μg 
protein were separated with constant 130 V by using 10% SDS-PAGE at rt, and 
transferred with constant 400 mA to PVDF (polyvinylidene-difluoride) membranes 
(#162-0177 Bio-Rad) at 4°C. Membranes were blocked in TBST (tris buffered saline 
with 0.1% TWEEN 20) supplemented with 5% (m/V) skimmed milk (1 h, rt), probed 
with primary antibodies at 1:1000 (TBST with 1% (m/V) BSA, overnight, 4°C), washed 
three times with TBST (10 min, rt) and incubated with HRP-conjugated (horseradish 
peroxidase) secondary antibodies (anti-rabbit 1:2000, anti-mouse 1:4000) in TBST 
supplemented with 1% (m/V) BSA for 1 h at rt. After washing three times (TBST, 
10 min, rt) proteins of interest were visualized with chemiluminescence reagent (1-
10 min, rt, Western Lightning Plus-ECL, PerkinElmer) on CL-XPosure Films (Thermo 
Scientific, MA, USA). Primary antibodies were purchased from Cell Signaling 
Technologies (Danvers, MA, USA): Aurora A (#4718), phospho-Aurora A/B/C 
(#2914), Aurora B (#3094), Histone H3 (#3638), phospho-Histone H3 (#3377) and 
from Sigma-Aldrich (St. Louis, MO, USA): Tubulin (T9026). HRP-conjugated 
secondary antibodies were purchased from Cell Signaling Technologies: anti-rabbit 
(#7074) and anti-mouse (#7076). 
 
Fluorescence microscopy 
HT-29 cells were seeded to 96 well Ibidi µ-plate (89626) at 10000 cells/well density in 
250 μl complete medium. After 24 h medium was removed and cultures were treated 
with indicated inhibitor concentrations or vehicle (DMSO) dissolved in 250 μl complete 
medium and incubated for additional 24 h at 37°C in a humidified, 5% CO2 incubator. 
At the end of the treatment cells were washed with 250 μl PBS, fixed with 150 μl 4% 
(V/V) formalin solution (10 min, rt) and washed twice with PBS (10 min, rt). Then cells 
were permeabilized by 150 μl PBS supplemented with 0.1% Triton X-100 detergent 
(10 min, rt) and washed twice with PBS for (10 min, rt). Prepared cells were incubated 
with anti-tubulin antibody (1:10000, Sigma T9026) dissolved in PBS supplemented 
with 10% (m/V) BSA (overnight, 4°C). Samples were washed with PBS once for 1 min 
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and three times for 10 min (rt) then incubated with Alexa 488-conjugated secondary 
antibody (1:500, Life Technologies A11001) dissolved in PBS supplemented with 10% 
(m/V) BSA (1 h, rt). 
Samples were washed with PBS once for 1 min and three times for 10 min then nuclei 
were stained with 150 μl PBS containing 1 μg/ml DAPI (10 min, rt). After removing 
DAPI solution, cells were covered with 200 μl PBS and observed with Zeiss Axiovert 
200M fluorescence microscope and AxioVision 3.1 software. Images were uniformly 
taken by using the 63x oil-immersion objective and filter set 25 for DAPI (excitation 
filter TBP 400/495/570 nm, mirror FT 410/505/584 nm, emission filter TBP 
460/530/610 nm) and filter set 10 for Alexa 488 (excitation filter BP 450-490 nm, 
mirror 510 nm, emission filter BP 515-565 nm). Merged images were created by FIJI 
software. 
 
Drug combination experiments 
For drug combination studies cell viability was measured with MTT assay as described 
above. All compounds were applied in either monotherapy and also in combination at a 
constant ratio of 1:1 as a serial three-fold dilution starting from 30 µM. Mean cell 
viability data were transformed to be between 0 and 1 as required by the CompuSyn® 
software. Therefore mean values equal to or above 1 were set to 0.99 and mean values 
equal to or under 0 to 0.005. Transformed cell viability data of monotherapy and 
combination treatments were compared using CompuSyn® v1.0 software (ComboSyn 
Inc.) and CI (combination index) values were calculated. Only the CI value at the IC50 
value (0.5 Fa – fraction affected) of a given combination was considered. In practice 
CI < 1 indicates synergistic, CI = 1 additive and CI > 1 antagonistic effects, 
respectively. A more refined classification to interpret the CI values provided by 
CompuSyn® is shown in Table 1.404 Accordingly, in this Thesis CI values under 0.7 
were considered synergism.  
DOI:10.14753/SE.2019.2277
42 
 
Table 1. Ranges of CI values calculated by CompuSyn® software and their description. 
Range of CI Description 
< 0.1 very strong synergism 
0.1 – 0.3 strong synergism 
0.3 – 0.7 synergism 
0.7 – 0.85 moderate synergism 
0.85 – 0.90 slight synergism 
0.90 – 1.10 nearly additive 
1.10 – 1.20 slight antagonism 
1.20 – 1.45 moderate antagonism 
1.45 – 3.30 antagonism 
3.30 – 10 strong antagonism 
> 10 very strong antagonism 
 
Statistical analysis 
Cell viability, enzyme inhibition and apoptosis induction data are expressed as mean 
value ± standard deviation. Flow cytometry data were analysed by Student’s t-test (two-
sided, unpaired) using Excel software. Statistical significance was defined as p < 0.05. 
Recombinant kinase inhibition measurements were evaluated by calculating the Z’ 
value: Z’=1-((3SDmax+3SDmin)/(AVmax-AVmin)) where SDmax is the standard deviation 
of the positive, SDmin is of the negative control, AVmax is the mean value of the positive 
and AVmin is of the negative controls. Only measurements of a Z’ value higher than 0.5 
were accepted for evaluation. 
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Docking methods 
For the in silico modelling the previously determined crystal structures of Aurora A 
(PDB ID: 4J8M) and Aurora B-INCENP (PDB ID: 4AF3) proteins were used. All 
calculations were carried out with the modules of Schrödinger Suites 2015-3 
(Schrödinger, LLC, New York, NY) in Maestro. Before docking in-house compounds, 
the proteins were prepared by removing water molecules and adding hydrogens to the 
residues with Protein Preparation Wizard. After performing restrained minimization 
using OPLS_2005 force field, the grid box were centred at the bound ligands of the 
crystal structures. The 3D structure of the ligand was determined by LigPrep at pH 7.4 
by using OPLS_2005 force field.  
The binding modes of ligands were identified by Induced Fit docking using Extended 
Sampling protocol. The best binding poses were chosen for further investigation based 
on the IFD Score, the docking score, and visual inspection of poses of the docked 
ligand. All in silico molecular modelling were performed by Marcell Krekó at Vichem 
Chemie Ltd. 
 
Solubility measurements: 
DMSO stock compound solutions of 5 mM were diluted in DMSO (control) or 
phosphate buffer (pH 7.4 and pH 2.0) to a 120 µM final concentration. These samples 
were incubated for 24 hours at rt followed by centrifugation (3700 rpm, 30 min, rt). 
Next, 40 µl of the supernatants were injected into RP-HPLC and the AUC (Area Unit 
under the Curve) values were measured on a sample specific wavelength. AUC value of 
every buffered sample was divided by the AUC value of the DMSO control sample at 
the same wavelength. Gradient elution: eluent A – 0.1% formic acid in water, eluent B – 
MeCN. The column was XBridge C18 3.5 µm 4.6 x 50 mm. All work was performed by 
Eszter Illyés and Zsófia Czudor at Vichem Ltd.  
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4. Results 
 
Selecting the eight best benzothiophene-3-carboxamide derivatives in cell viability 
assay 
During preliminary, in vitro recombinant Aurora A and B enzyme inhibition tests more 
than 100 benzothiophene-3-carboxamide derivatives were measured at 10 µM ATP 
concentration (data not shown). Many of those compounds had promising effect 
(% value) on both kinases. All of them had variable substituents at three positions (R1, 
R2 and R3) as presented on Figure 6. 
 
Figure 6. Chemical structure of compound 1. Circles indicate the three important 
substituents and sites of difference in the benzothiophene-3-carboxamide compound 
family. 
 
According to the preliminary enzyme inhibition data I assessed the IC50 value of 84 
selected benzothiophene-3-carboxamide derivatives with MTT cell viability assay (48 h 
treatment). As model cancer cell line HCT 116 cells were chosen. Since compounds 
differing in side group R2 have parallel synthesis paths, cyclopropanoyl-amino and 
methylureido series can be distinguished. Following the logic of chemistry and for 
clarity I will discuss the cell viability IC50 data in two sections. 
SAR of the 84 selected benzothiophene-3-carboxamide derivatives was quite coherent. 
The substance of SAR observations is presented with 33 molecules which inhibited the 
viability of HCT 116 cells most (Table 2 and 3). For the analysis of SAR see chapter 5, 
Discussion. According to cell viability data I choose compounds 9, 11, 17, 21, 22, 25, 
28 and 31 with an IC50 value equal to or below 0.6 µM for further investigations. The 
cellular effect of these eight compounds was comparable to, or surpassed the pan-AKI 
VX-680 and the Aurora A inhibitor MLN8054 in MTT cell viability assay. 
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Table 2. The cyclopropanoyl-amino series. Core structure and inhibition of cell 
viability of compounds 1-8 on HCT 116 cell line using MTT assay. IC50 values are the 
mean of at least three independent experiments ± standard deviation (SD). 
 
Compound R3 IC50 ± SD [µM] 
1 
 
1.388 ± 0.964 
2 
 
9.982 ± 0.032 
3 
 
1.391 ± 0.291 
4 
 
2.356 ± 0.320 
5 
 
6.195 ± 1.104 
6 
 
4.582 ± 1.027 
7 
 
0.764 ± 0.226 
8 
 
9.009 ± 0.994 
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Table 3. The methylureido series. Core structure and cell viability inhibition of 
compounds 9-33 as well as VX-680 and MLN8054 as reference AKIs on HCT 116 cell 
line using MTT assay. IC50 values are the mean of at least three independent 
experiments ± standard deviation (SD). Cpd = compound. 
 
Cpd R1 R3 IC50 ± SD [µM] Cpd R
1 R3 IC50 ± SD [µM] 
9 
 
0.313 ± 
0.164 23 
 
 
1.297 ± 
0.484 
10 
 
1.774 ± 
0.778 24   
0.952 ± 
0.188 
11 
 
0.474 
±0.341 25 
 
 
0.287 ± 
0.167 
12 
 
3.802 ± 
1.168 26   
0.790 ± 
0.073 
13 
 
3.407 ± 
1.408 27 
 
 
1.532 ± 
0.413 
14 
 
1.024 ± 
0.422 28 
 
 
0.338 ± 
0.170 
15 6.997 ± 3.133 29 
 
 
2.326 ± 
1.014 
16 
 
1.465 ± 
0.222 30   
2.356 ± 
0.218 
17 
 
0.600 ± 
0.053 31 
 
0.556 ± 
0.288 
18 
 
0.773 ± 
0.288 32  
9.779 ± 
0.240 
19 
 
2.579 ± 
0.425 33 
 
1.185 ± 
0.429 
20 
 
0.946 ± 
0.352 VX-680 
0.449 ± 
0.149 
21 
 
0.295 ± 
0.085 MLN8054 
0.850 ± 
0.070 
22 
 
0.411 ± 
0.224     
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In vitro recombinant Aurora A and B kinase inhibition assay 
I measured the IC50 values of compounds 9, 11, 17, 21, 22, 25, 28 and 31 in in vitro 
recombinant Aurora A and B kinase inhibition assays. For IC50 measurements ATP 
concentrations were adjusted to the KM[ATP] value of the particular enzyme. As reference 
compound the pan-AKI VX-680 was used. According to the IC50 values most of the 
compounds performed better than VX-680 on both kinases. At the same time, IC50 
values of the eight compounds were very similar, the exceptions being 21 and 31 with 
an even better effect on Aurora A than on Aurora B (Table 4). 
 
Table 4. IC50 values of the hit compounds in in vitro recombinant Aurora A and B 
kinase assay. Values are the mean of at least three independent experiments ± standard 
deviation (SD). 
Compound 
Enzymatic assay IC50 ± SD [µM] 
Aurora A Aurora B 
9 0.037 ± 0.017 0.035 ± 0.014 
11 0.095 ± 0.015 0.046 ± 0.026 
17 0.024 ± 0.012 0.038 ± 0.011 
21 0.009 ± 0.003 0.023 ± 0.016 
22 0.021 ± 0.007 0.011 ± 0.006 
25 0.032 ± 0.017 0.029 ± 0.014 
28 0.080 ± 0.037 0.048 ± 0.023 
31 0.005 ± 0.001 0.017 ± 0.009 
VX-680 0.127 ± 0.038 0.043 ± 0.031 
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Assessing DNA content by flow cytometry 
Since all eight selected compounds inhibited Aurora B in the recombinant kinase assay I 
measured the ratio of multinucleated (mostly octaploid – 8n) cell population that failed 
cytokinesis upon compound treatment. All compounds were applied uniformly at 
100 nM and for 24 h. Then DNA content was stained with PI and analysed by using 
flow cytometer. According to the measurements, none of the compounds induced 
apoptosis (indicated by percentage of cells with attenuated DNA content – the subG1 
fraction) compared to vehicle (DMSO) treated control. However, appearance of 
octaploid cells was explicit in case of VX-680 and in-house compounds 9, 11, 25, 28 
and 31 (Figure 7). 
 
 
Figure 7. HCT 116 cells treated with reference AKIs and eight selected in-house 
compounds at 100 nM for 24 h. Apoptotic and octaploid cell fractions are depicted as a 
percentage of total cell population. Treatment groups were replicated at least three 
times. Error bars represent standard deviation (SD). *denotes significant difference 
compared to DMSO control (p < 0.05) according to Student’s t-test.  
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These treatments were repeated also at 1 µM compound concentration. The same two 
reference AKIs, and two in-house compounds were chosen: 25 that increased ploidity 
and 21 that did not. Interestingly, at 1 µM also previously ineffective compounds like 
MLN8054 or 21 inhibited cytokinesis and created octaploid cells. Whereas compounds 
that were effective inhibitors of cytokinesis at 100 nM – like VX-680 or 25 – showed a 
slightly decreased effect (Figure 8). 
 
 
Figure 8. HCT 116 cells were treated with AKIs and in-house compounds at 100 nM or 
1 µM for 24 h. Octaploid cell fraction is depicted as a percentage of total cell 
population. Treatment groups were replicated at least two times; error bars represent 
standard deviation (SD). 
 
Assessing DNA content by fluorescence microscopy 
I treated HT-29 cells with reference compounds VX-680, MLN8054, MLN8237 and in-
house compounds 21 and 25. Cell morphology was observed by using fluorescence 
microscope (Figure 9/1 and 9/2). Similarly to flow cytometry results VX-680 and 25 
inhibited cytokinesis already at 100 nM and as a result larger-than-normal cells with 
two or more nuclei appeared in the culture. Compounds 21, MLN8054 and MLN8237 
had no such effect at 100 nM, nor did DMSO. However, at 1 µM also 21 and MLN8237 
created multinucleated cells, while MLN8054 still did not. 
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Figure 9/1. Merged images of HT-29 cells treated with vehicle (DMSO) or reference 
AKIs VX-680 and MLN8054 at 100 nM or 1 µM for 24 h. Blue (DAPI) staining 
indicates nuclei, green (Alexa488) tubulin. Pictures were taken at 63x magnification. 
Red arrows point to cells with at least two nuclei. 
DOI:10.14753/SE.2019.2277
51 
 
 
Figure 9/2. Merged images of HT-29 cells treated with in-house compounds 21, 25 and 
reference AKI MLN8237 at 100 nM or 1 µM for 24 h. Blue (DAPI) staining indicates 
nuclei, green (Alexa488) tubulin. Pictures were taken at 63x magnification. Red arrows 
point to cells with at least two nuclei.  
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Assessing induction of apoptosis by flow cytometry 
I used PI and Annexin V-FLUOS dual staining to measure the apoptotic fraction of 
compound treated HCT 116 cells. Intriguingly, considerable percentage of apoptotic 
cells were detected only after 72 h treatment in case of some compounds (Figure 10 and 
Table 5). Moreover, the pattern was the same as observed in case of DNA content: 
VX-680 and compounds 9, 11, 25, 28 induced substantial apoptosis while MLN 8054, 
17, 21, 22 only a moderate one (Figure 11). The most effective in-house compound was 
25 that – like VX-680 – induced apoptosis in almost 20% of the cells. Again, the 
experiment was repeated also at 1 µM compound concentration. The results were 
similar to single PI staining: at 1 µM also previously ineffective compounds – like 21 – 
induced apoptosis (Figure 12). 
 
 
Figure 10. Apoptotic fraction of HCT 116 cells measured by PI and Annexin V-
FLUOS staining after 24, 48 and 72 h treatment at 100 nM inhibitor concentration 
uniformly. DMSO – vehicle control. Values are the mean of at least two independent 
experiments.  
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Table 5. Apoptotic fraction of HCT 116 cells measured by PI and Annexin V-FLUOS 
staining after 24, 48 and 72 h treatment at 100 nM inhibitor concentration uniformly. 
DMSO – vehicle control. Mean values ± standard deviation (SD) of the data depicted on 
Figure 10. 
 DMSO control VX-680 MLN8054 21 25 
24 h 2.90 ± 1.08 8.13 ± 5.76 3.69 ± 1.56 2.82 ± 1.17 4.77 ± 1.65 
48 h 2.20 ± 0.49 7.51 ± 1.03 2.64 ± 0.81 2.25 ± 0.50 6.38 ± 0.97 
72 h 2.84 ± 0.01 18.13 ± 1.29 3.33 ± 0.33 3.66 ± 1.28 18.58 ± 0.94 
 
 
 
Figure 11. Fraction of HCT 116 cells undergoing apoptosis measured by PI and 
Annexin V-FLUOS staining after 72 h treatment. Reference compounds VX-680 and 
MLN8054 and eight selected in-house compounds were used at 100 nM. DMSO – 
vehicle control. Values are the mean of at least four independent experiments. Error 
bars represent standard deviation (SD), *denotes significant difference compared to 
DMSO control (p < 0.05) according to Student’s t-test. 
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Figure 12. Fraction of HCT 116 cells undergoing apoptosis measured by PI and 
Annexin V-FLUOS staining after 72 h treatment. Reference compounds VX-680 and 
MLN8054 and selected in-house compounds 21 and 25 were used at 100 nM or 1 µM, 
respectively. DMSO – vehicle control. Values are the mean of at least two independent 
experiments; error bars represent standard deviation (SD). 
 
Testing cell viability inhibition of primer fibroblast cell culture 
According to cell viability and apoptosis measurements I choose 25 as the primary hit 
molecule of the eight selected benzotiophene-3-carboxamides. However, compound 21 
was also studied in some of the following experiments just for comparison (Figure 13). 
  
 
Figure 13. Chemical structure of benzotiophene-3-carboxamide derivatives A) 21 and 
B) 25.  
DOI:10.14753/SE.2019.2277
55 
 
To make sure that these most important compounds do not affect viability of healthy 
cells also primer fibroblasts were treated with them. All circumstances were the same as 
in the HCT 116 experiments except compound concentration which was fixed at 1 µM. 
Data clearly present that none of the compounds influenced viability of fibroblast cells 
considerably. (Figure 14) 
 
 
Figure 14. Cell viability of primer fibroblast cells after 48 hours compound treatment. 
Reference AKIs were VX-680, MLN8054 and MLN8237, in-house compounds were 21 
and 25. An MTT assay, vehicle control was DMSO. Percentage (%) values are the mean 
of two independent experiments ± standard deviation (SD). 
 
Western blot analysis 
To explore mechanism of action of in-house compounds 21 and 25 in the HCT 116 cells 
we performed Western blot experiments. According to levels of autophosphorylated 
Aurora A and B, 21 inhibited Aurora A activity completely at 500 nM while Aurora B 
partially at 1 µM. So in cells 21 behaves similarly to reference compound MLN8237, a 
selective Aurora A inhibitor (Figure 15). At the same time 25 decreased activity of both 
Aurora kinases equipotent to VX-680, already at 100 nM. Also Histone H3 Serine10 
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phosphorilation was diminished by 25 at 100 nM which is the sure sign of absent 
Aurora B function. Meanwhile total protein levels of Aurora A, Aurora B and Histone 
H3 remained unchanged at all concentrations (Figure 16). Therefore 25 is considered a 
potent, pan-AKI – unlike 21 which proved to be less potent but selective to Aurora A. 
 
 
Figure 15. Cellular total protein level and phosphorylation status of Aurora kinases A, 
B and Histone H3 after 3 h treatment at three concentrations of reference compound 
MLN8237 and 21. Representative blot of three independent experiments on HCT 116 
cells. 
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Figure 16. Cellular total protein level and phosphorylation status of Aurora kinases A, 
B and Histone H3 after 3 h treatment at three concentrations of 25 and VX-680 a pan-
AKI. Representative blot of three independent experiments on HCT 116 cells. 
 
Development of EGFR–c-Met dual inhibitors. 
In one of our alternative project also focusing to signal transduction therapy we 
developed an EGFR–c-Met dual TKI. The aim was to decrease the viability of 
activating mutant EGFR-driven but simultaneously EGFR TKI resistant NSCLC cell 
lines.370 First, five in vitro recombinant kinase assays were adjusted and optimised 
(including KM[ATP] determination): wild-type EGFR (EGFRwt), activating mutant 
EGFRs (EGFRL858R and EGFRDel), activating and resistant mutant EGFR 
(EGFRL858R/T790M) and c-Met. Then extensive screening of the EVL™ of Vichem Ltd. 
was performed by using these five enzymes. As a result few compounds were identified 
based on a novel ‘N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide’ core structure. 
Sulfonamides were tested on relevant NSCLC cell lines, as well. During lead 
optimization several further derivatives were synthetized and tested in the same 
recombinant kinase and cellular assays. The reference inhibitor for EGFR was erlotinib, 
for c-Met crizotinib and BMS-777607. The new sulphonamide derivatives could have 
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been divided roughly to two subgroups: compounds inhibiting rather EGFR varieties or 
rather c-Met. Only one compound, 34 had low enough IC50 values on wild-type or 
activating mutant EGFRs and c-Met kinases (Figure 17). No potent inhibitor of the 
resistant mutant variety of EGFR (EGFRL858R/T790M) was found in the EVL™ or among 
the new derivatives. In a recombinant kinase-based ATP-competitivity assay 34 proved 
to be a dedicated type I-II inhibitor that occupied the ATP-binding pocket of both 
EGFRwt and c-Met. During further cell-based experiments 34 indeed reduced EGFR and 
c-Met autophosphorylation (thus activity), abrogated downstream signalling pathways 
and induced apoptosis at an extent comparable to reference inhibitor erlotinib. 
 
 
Figure 17. Chemical structure and in vitro recombinant c-Met, EGFRwt and EGFRL858R 
enzyme inhibition values of compound 34. IC50 values are the mean of at least three 
independent experiments ± standard deviation (SD). 
 
Drug combination experiments 
I examined the potency of the two best in-house compounds from the AKI and the 
EGFR–c-Met TKI development projects in concurrent treatment. HCT 116 and HT-29 
colon carcinoma cell lines were treated with 25 or VX-680 in combination with other 
targeted agents that were already known to synergise with AKIs, and compound 34 
(Table 6). Cell viability was measured using MTT assay and CI values were calculated 
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by using the data. According to the CI values 9 of the 32 combinations showed 
synergism (0.7 > CI > 0.3) and 13 strong or very strong synergism (0.3 > CI). Both cell 
lines were sensitive to similar drug combinations and both 25 and VX-680 behaved 
alike. So the effect of 25 showed the pattern of a functional AKI in this setting. 
 
Table 6. Effect of 25 or VX-680 on cell viability in combination with various targeted 
agents. Mean inhibition values of at least three independent experiments were used to 
calculate CI by CompuSyn® software. Yellow marking indicates combinations with 
synergism (0.7 > CI > 0.3), orange with strong synergism (0.3 > CI > 0.1) and red with 
very strong synergism (0.1 > CI). 
Cell line HCT 116 HT-29 
Compound 25 VX-680 25 VX-680 
GSK2126458 1.042 0.511 1.044 6.330 
Erlotinib 0.250 0.503 0.075 0.125 
Trichostatin A 0.195 0.321 0.185 0.111 
Dasatinib 1.000 0.561 0.073 0.097 
Lonafarnib 0.755 1.114 0.198 0.340 
Carfilzomib 113.078 669.014 0.050 1.827 
Crizotinib 0.136 0.207 0.102 0.212 
34 0.393 0.308 0.395 0.836 
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In silico compound docking 
We utilized Schrödinger software for in silico docking to investigate the Aurora kinase-
binding mode of 25 (Figure 18). We can sum up our observations in six points: 
1) The 3-carboxamide moiety forms hydrogen bonds with the -NH and -CO groups of 
the protein backbone hinge region (A213 and E211 in Aurora A; A157 and E155 in 
Aurora B).  
2) The nitrogens of R2 also form hydrogen bonds with the backbone carbonyl oxygen of 
the aforementioned alanines. Many KIs form hydrogen bond with the hinge region,300 
which is also important in case of AKIs.405  
3) The oxygen of the sulphonamide group interacts with the catalytic lysine residue 
(K162 in Aurora A and K106 in Aurora B). 
4) Further hydrogen bonds were detected with residues D274 (part of the DFG-motif), 
R137 and R220 in Aurora A, and with A217 in Aurora B. 
5) In case of Aurora B a π-π stacking is present between the benzothiophene ring and 
F88. 
6) According to Schrödinger software the docking score – that is the binding energy – 
of 25 (-10.894 kcal/mol for Aurora A and -9.054 kcal/mol for Aurora B) is comparable 
to of VX-680 (-10.587 kcal/mol for Aurora A and -9.224 kcal/mol for Aurora B). 
All these observations corroborate that 25 indeed fits into the ATP-binding cleft of both 
Aurora A and B kinases, forms several secondary chemical bonds there and has a 
binding affinity comparable to VX-680. 
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Figure 18. Molecular docking of 25 into the ATP-binding site of Aurora A (PBD ID: 
4J8M) and Aurora B-INCENP (PDB ID: 4AF3) crystal structures. Interacting residues 
are grey while 25 highlighted green. H-bonds are indicated by yellow, while π-π 
stacking by blue dashed lines.  
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Solubility measurements 
Solubility of few benzotiophene-3-carboxamide compounds was measured at two 
physiologically relevant pH values (Table 7). Generally, in-house compounds had poor 
solubility at both pH values compared to reference compounds. However, the solubility 
limit of most compounds was higher than 1 µM which was applied in the most 
important experiments. Concentrations higher than 1 µM were only used during cell 
viability and drug combination experiments (30 µM, 10 µM and 3 µM, respectively). 
Note that 21 is more soluble than 25 at both pH values. 
 
Table 7. Solubility values of some benzotiophene-3-carboxamides at pH 7.4 and pH 2. 
Seven of the eight selected compounds are marked with grey. All values are the means 
of two independent measurements. 
 Solubility (µM; max 120) 
Compound pH 7.4 pH 2.0 
9 1.7 1.3 
11 3.6 2.6 
14 0.0 0.0 
17 13.6 11.4 
18 3.0 2.8 
20 4.6 4.3 
21 13.1 8.0 
23 6.7 3.3 
24 3.9 1.1 
25 1.9 1.8 
26 12.8 5.3 
27 1.1 0.0 
28 1.4 1.6 
31 6.2 4.2 
33 4.8 3.7 
VX-680 120 120 
MLN8054 98.25 5.80 
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Kinase selectivity panel 
Inhibitor potency of compounds 21 and 25 was assessed on the most important driver 
kinases to approximate their in vivo selectivity (Table 8/1 and 8/2). All work was 
performed by Proteros GmbH. Both compounds inhibit quite a few kinases beside 
Aurora A and B, so rather qualify as multi-kinase inhibitors. 
 
Table 8/1. In vitro recombinant kinase inhibition values (%) of 21 (at 1 µM) and 25 (at 
10 µM) on 36 kinases. Data of Aurora A kinase is marked with grey. Order of kinases in 
the table is set according to the inhibition values of 25. ND – not determined. 
Kinase 21 25 
AXL 37.21 112.17 
VEGFR2 68.15 108.71 
c-Src 94.39 104.99 
Aurora A 114.04 100.39 
ABL 88.79 100.35 
JAK3 54.64 99.63 
RET 97.17 98.37 
PAK4 11.19 95.67 
TrkA 46.85 95.35 
PDGFR-β 61.29 88.03 
DDR1 75.92 84.43 
FGFR3 14.42 81.62 
PLK3 ND 78.73 
c-Kit 28.88 71.58 
CHK1 16.41 62.84 
FLT3 46.63 56.82 
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Table 8/2. In vitro recombinant kinase inhibition values (%) of 21 (at 1 µM) and 25 (at 
10 µM) on 36 kinases. Order of kinases in the table is set according to the inhibition 
values of 25. ND – not determined. 
Kinase 21 25 
B-RAF -0.30 53.47 
c-Met 2.76 47.44 
CDK4/CycD1 27.00 44.13 
ErbB2 ND 35.87 
TIE2 0.75 35.69 
PIM1 41.60 35.68 
CDK2/CYCA 22.77 33.85 
INSR 3.00 28.46 
PAK1 5.28 26.73 
PKCα 17.94 21.44 
CSK 19.54 17.27 
SYK 51.10 16.56 
IKK-β 30.67 16.20 
IRAK4 8.14 15.96 
AKT1 ND 13.63 
ZIPK (DABK3) 39.62 12.93 
MAPK-ERK1 17.64 12.38 
JNK1 ND 12.16 
ROCK2 15.67 11.82 
mTOR 3.66 8.62 
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5. Discussion 
 
The common denominator of conventional cytotoxic cancer therapeutic approaches is to 
destroy dividing cells, regardless they are cancerous or healthy. Next-generation drugs 
are much more precise – they target the very protein that malfunctions and drives the 
given cancer. Unfortunately, even the targeting of such a strong, proven driver like 
EGFR leads fast to resistance. So it is worth to consider simultaneous inhibition of 
multiple drivers and even non-driver kinases to beat cancer. 
Aurora kinases are fundamental, conserved regulators of every eukaryotic cell division. 
While their inhibition seems to have a general, non-targeted effect like conventional 
cytotoxic therapeutics, it is also well known that Aurora kinases often have increased 
activity in various cancer types. They do not seem to be drivers, but due to their 
ubiquity (they expressed in every dividing human cell) and central role (the essence of 
cancer cells is perpetual division) they remain promising drug targets for mono- or 
combination therapies. However, the development of AKIs proved to be a hard task. 
Therefore I surveyed a family of benzotiophene-3-carboxamide derivatives as potential 
AKIs in the laboratories of Vichem Ltd. and the Pathobiochemistry Research Group at 
Semmelweis University. All the experimental work in the Thesis was performed by me, 
unless indicated else in the Materials and Methods (chapter 3) or Results (chapter 4) 
sections. I used various methods available to me so I got data diverse enough to 
summarise the project and make some interesting statements. 
 
Preliminary experiments 
Recombinant Aurora A and B kinases were purchased by Vichem Ltd. and after 
adjusting their optimal buffer conditions used to screen the EVL™ to find potential new 
AKIs. These preliminary tests provided only % inhibition values and were performed 
uniformly at 10 µM ATP concentration which is suboptimal for most kinases and 
unfavourable for inhibitors of some types. Therefore these percentage inhibition values 
are not too precise. Yet, benzotiophene-3-carboxamide derivatives were unambiguously 
identified as compound family with promising AKI properties during this first medium-
throughput screening step. 
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The NCL™ of Vichem Ltd. contains almost 200 benzothiophene-3-carboxamide 
derivatives, about half of which had preliminary Aurora A and B enzyme inhibition data 
at the time I entered the project. Since many of them were not effective inhibitors of 
either Aurora kinase, I considered their structure (as a preliminary SAR study) and 
excluded many compounds from the following studies.  
 
The IC50 determination using cellular screen. 
As we have seen, inhibition of Aurora kinases directly hinders proliferation of cells: 
lack of Aurora A compromises mitotic progression, while inhibition of Aurora B 
abrogates cytokinesis and induces polyploidy. Both phenomena result in reduced cell 
number, loss of Aurora B function even marked phenotypic alteration. Therefore I 
decided to determine the IC50 values of 84 selected benzotiophene-3-carboxamide 
compounds on cancer cell lines first, instead of kinase assay. This reverse logic is rarely 
utilized, but given the well-known discrepancy of kinase and cellular screen data, has its 
advantages.406 This way IC50 values not only permit precise ranking of compounds but 
also provide some information on the behaviour of inhibitors inside human cells. For 
the following cell-based experiments I choose two colon carcinoma cell lines, both of 
which express elevated level of Aurora A407 and frequently utilized for testing AKIs: 
HCT 116408, 320 and HT-29409, 410. Regarding the driver constitution of this two cell lines: 
- both cell lines harbour wild-type EGFR,242 
- VEGFR is overexpressesed in HCT 116 but nearly absent in HT-29.411 
- HCT 116 harbours mutant K-RAS and PI3K [Broad Institute Cancer Cell Line 
Encyclopedia].412 while both kinases are wild-type in HT-29. 
- In turn, mutant form of BRAF [Broad Institute Cancer Cell Line Encyclopedia] and 
p53 (R273H – decreased activity) proteins are expressed in HT-29.413 
 
SAR study of cell viability inhibition data. 
Even the smallest alteration in the structure of a small molecule may profoundly alter its 
physicochemical properties (like solubility or membrane permeability) and so 
pharmacokinetics – that is the fate of drug in the organism (ADME criteria) and 
pharmacodynamics – that is the effect the drug exerts on the organism. According to the 
cell viability IC50 data I could make several intriguing assertions regarding the effect of 
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substituents (R1, R2 and R3) on activity. I discuss these relationships using a group of 
thirty-three representative compounds that also include the most effective 
benzotiophene-3-carboxamides. First, let’s see the cyclopropanoyl-amino series 
(Chapter 4, Table 2) where R3 – the only variable substituent – is represented with aryl, 
alkyl, cycloalkyl and heteroaryl groups: 
- Compared to compound 1 (R3 phenyl) only 7 (R3 methylpyrazol) augmented cell 
viability inhibition. 
- The lack of delocalized electron pairs in the cyclohexyl group greatly reduced activity 
of 2 compared to 1. 
- Similarly, hydrophobic alkyl side chains (3 methyl, 4 ethyl, 5 propyl) were 
disadvantageous – the longer the chain, the greater extent. 
In case of the methlyamine series (Chapter 4, Table 3) R3 substituents were more 
diverse. 
- The single change of group R2 to methylureido significantly increased cell viability 
inhibition in many cases: 1 vs. 9, 4 vs. 17, 5 vs. 18, 6 vs. 25, 7 vs. 31, 8 vs. 11. 
Molecular docking reveals the underlying mechanism: the nitrogens of the methylureido 
group form two hydrogen bonds with the hinge region of Aurora kinases while the 
cyclopropanoyl-amino group presumably only one. 
- In case of methyl substituents of R3 there was no significant difference in the 
biological effect of the cyclopropanoyl-amino (3) or the methylureido (16) derivatives. 
- Among alkyl substituents of R3 ethyl (17) was the best compared to longer (18, 20) or 
branching (19) ones. Though, even 17 did not approximated the cellular effect of 9. 
- Substitution on the R3 benzene ring of 9 resulted in roughly similar IC50 only when the 
methyl group was at meta position (11). 
- A secondary or tertiary amine side chain at R3 (22 and 21) was equally effective to 9 
and definitely more favourable than the alkyl chains of similar shape and size (20 and 
19). 
- Evaluating the heterocyclic substituents at position R3, the 2-furan derivative (23) had 
weaker cell viability inhibition effect than the 2-thiophene (25) or the methylpyrazole 
(31) one. 
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- Similarly to the R3-phenyl substitution, a methyl group on the thiophene ring was 
tolerated only at „meta” position (28), but not „para” (29) – considering the longer 
radius of the sulphur atom. 
- Swapping the R1 isopropyl group to methyl or cyclopropyl group consistently 
abolished the cellular effect (23 vs. 24, 25 vs. 26 and 27, 31 vs. 32 and 33). 
Unfortunately in silico docking does not reveal the reason behind this phenomenon. 
It would have been interesting to further study SAR but I decided not to, because: 
1) cell viability screen of another cell line and binding energies of in silico docking 
scores of these thirty-three compounds could not corroborate these observations (Data 
not shown). 
2) due to the aforementioned reasons cellular screen is not an ideal model system for 
SAR studies. One can never be sure whether the observed cellular effect is due to 
altered potency of enzyme inhibition or metabolism/secretion of the drug. 
3) My topmost goal was to corroborate the AKI potency of benzotiophene-3-
carboxamides and characterise a hit compound. 
 
Corroborating KI potency in in vitro assay. 
According to the cell viability assay I selected the eight most potent compounds (9, 11, 
17, 21, 22, 25, 28 and 31) with an IC50 value below 0.6 µM on HCT 116 cells. As the 
first subsequent assay I determined the Aurora A and B kinase inhibition IC50 values of 
these eight benzotiophene-3-carboxamide derivatives. For the IC50 determination ATP 
concentrations were set to the KM[ATP] value of each kinase. The KM[ATP] values had to 
be measured in a separate set of experiments. The KM[ATP] value relates to the affinity of 
ATP to the particular kinase. Running the kinase assay at the KM[ATP] concentration has 
the advantage of making the IC50 values of different inhibitors (type I, II, etc.) 
comparable.414 According to the optimized in vitro recombinant kinase assay all eight 
compounds were comparably effective to or better than reference compound VX-680. 
Furthermore, most compounds proved to be equally effective Aurora A and B KIs, the 
only exceptions being compound 21 and 31 that were one order of magnitude more 
efficient on Aurora A than on B. While 21 had the second lowest IC50 on HCT 116 cells 
(identical to 25), 31 was considerably less effective. At the same time, despite their 
identical potency on Aurora B in vitro, 31 induced apoptosis at 100 nM but 21 not. 
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These facts point to the existence of unknown mechanisms modulating cellular effect of 
benzotiophene-3-carboxamides. Regarding compound 25, western blot and in silico 
docking experiments also hint to its similar affinity to both Aurora kinases. Binding 
poses of 25 with lowest docking score and binding energy in the ATP-binding sites of 
both Aurora A and B kinases were almost identical. This result is not surprising, since 
the structure and the ATP-binding pockets of Aurora A and B kinases is very alike (also 
the difference in their regulated substrates is rather the consequence of different cellular 
localisation and protein partners and not substrate selectivity), that is why highly 
isoform selective (type I or II) AKIs are rare.415 
 
Analysing rise of DNA content and number of nuclei.  
As described in chapter 2.2.2.1., appearance of multinucleated, polyploid cells is a 
hallmark of Aurora B inhibition. Since all eight selected compounds proved to be 
effective Aurora B inhibitors in vitro I was curious whether they indeed reduced cell 
viability through Aurora B inhibition and cytokinesis failure. Therefore I quantified 
DNA content of compound treated HCT 116 cells by flow cytometry and took 
fluorescence microscopic images to visualize multiplication of nuclei. 
PI staining of ethanol-fixed cells reveals the amount of DNA in a flow cytometer. This 
way proportion of cell populations can be measured: G0 or G1 (with two series of 
chromosomes – 2n), G2/M (four series – 4n), multinucleated (8n and above) and 
apoptotic ones (called subG1 population – less than 2n). Of course within the 4n 
population cytokinesis-inhibited cells cannot be distinguished from normal ones in 
G2/M. The average duplication time of cancer cells is around one day so I decided to 
treat for 24 h to ensure the appearance of 8n population. It was less time than applied for 
cell viability determination. I applied compounds in these experiments uniformly at 100 
nM – this meant slightly higher concentration than their enzymatic IC50 values but a 
lower one than their cellular IC50 values. This way I suspected that Aurora kinases are 
already inhibited, but the possibility of off-target effects is minimal. Furthermore, this 
concentration is below the solubility limit of most compounds that are unfortunately 
rather low, compared to reference inhibitors VX-680 and MLN8054 (Chapter 4, Table 
7). This experimental setting proved to be optimal, because no compounds induced 
apoptosis during the treatment but I could observe signs of marked cytokinesis failure 
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and rise of multinucleated cells in case of some compounds (like 25), with both flow 
cytometry and fluorescence microscopy, respectively. The eight selected compounds 
could have been divided to cytokinesis inhibitors and non-inhibitors at 100 nM. 
Interestingly, this property did not correlate with cellular or enzymatic IC50 values. For 
example 21 and 25 or 17 and 31 were equally effective on HCT 116 cells yet, only 25 
and 31 inhibited cytokinesis at 100 nM. This notion again highlights that enzymatic data 
sometimes loosely correlate to cellular results because former miss differences in off-
target effect and physicochemical properties. 
It is well-known that selective inhibitors of Aurora A tend to inhibit also Aurora B at 
higher concentrations.416 Therefore I was curious whether the ineffective in-house 
compounds became effective at higher concentrations. So I repeated these experiments 
with the two reference compounds, the cytokinesis disruptor 25 and the non-disruptor 
21 at 1 µM, as well. Indeed, at the higher concentration also MLN8054 and 21 inhibited 
cytokinesis and created octaploid cells, but 21 much more. Whereas, compounds that 
were effective inhibitors of cytokinesis at 100 nM – like VX-680 or 25 – showed only a 
slightly decreased effect. 
According to fluorescence microscopic images MLN8054 proved to be a more selective 
Aurora A inhibitor than MLN8237 – latter induced more multinucleated cells at 1 uM. 
This observation is in concert with flow cytometry experiments, where the effect of 21 
improved more with increased concentration than of MLN8054. Therefore the Aurora 
kinase selectivity of 21 might be more similar to MLN8327 than MLN8054. 
 
Proving induction of apoptosis. 
According to scientific literature multinucleated cell state triggers apoptosis in time. To 
check this phenomenon I performed double PI and Annexin V-FLUOS staining with 
HCT 116 cells. Phosphatidylserine is a lipid situated exclusively in the inner plasma 
membrane of human cells. Flipping out of phosphatidylserine is a sign of apoptosis. The 
protein Annexin V is a specific binding partner of phosphatidylserine and utilized to 
mark cells undergoing apoptosis. First, I performed treatments at 100 nM for 24 (like in 
case of single PI staining) or 48 (like in case of cell viability measurements) hours but 
did not experience elevated level of apoptosis. Only after 72 could I detect considerable 
percentage of apoptotic cells in case of any compounds. This suggests that treated 
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cancer cells went through several cell divisions lacking cytokinesis without apoptosis 
induction. When those enormous, multinucleated cells finally underwent apoptosis, I 
observed two interesting correspondences: 
1) only hit compounds harbouring benzene or heterocyclic side groups at position R3 (9, 
11, 25, 28, 31) and the pan-Aurora inhibitor VX-680 induced apoptosis at 100 nM, 
whereas compounds bearing alkyl or alkyl-amine functions at position R3 (17, 21, 22) 
and the dedicated Aurora A inhibitor MLN8054 did not. (It is worth to note here, that 
according to the published effect of MLN8054, at 250 nM it is able to induce weak 
apoptosis of HCT 116 cells already after 24 hours.321) Therefore, I hypothesized that 
compounds 17, 21 and 22 – in spite of their excellent effect on Aurora B in vitro – did 
not inhibit Aurora B in cancer cells at 100 nM. 
2) This pattern of apoptosis induction was exactly the same as observed during DNA 
content analysis: only those compounds induced apoptosis which ones inhibited 
cytokinesis at 100 nM (VX-680, 9, 11, 25, 28, 31). Moreover, at 1 µM – in consonance 
with DNA content analysis – also compounds with alkyl or alkyl-amine R3 groups (like 
21) and MLN8054 induced apoptosis. 
These data underline that the new in-house compounds can be divided to inhibitors 
which blocked cytokinesis and induced apoptosis at low concentrations (like 25) and 
inhibitors which do neither (like 21). 
 
Corroborating the link between elevated DNA content and apoptosis. 
To further confirm that multinuclear cell state and apoptosis are the result of Aurora 
inhibition effect of benzotiophene-3-carboxamides we performed western blot 
experiments. Only two in-house compounds were tested: 21, a less potent, and 25, the 
most effective cytokinesis-blocking and apoptosis-inducing inhibitor. 
It came as a surprise that 21 proved to be an even weaker Aurora A and B inhibitor than 
MLN8237 in cells. At the same time 21 seemed to be selective to Aurora A, similarly to 
MLN8237 and in agreement with the in vitro kinase assay data. These observations 
somewhat contradicted the ones seen in fluorescence microscopy – where both 
compounds had similar potency. It is worth to emphasize though that treatment time 
was only 3 h in case of western blot experiments – opposed to 1 day in case of 
fluorescence microscopy. It is possible that even the weak Aurora B inhibition effect of 
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21 was enough to arrest cytokinesis and induce multinucleated cells in the long run. 
Another reason might be of course the different off-target profile of MLN8237320 
and 21. 
On the other hand, western blot analysis corroborated that both Aurora A and B are 
indeed the target of 25 in cancer cells. 25 diminishes phosphorylation (and so activity) 
of Aurora kinases even at 100 nM – better than 21 or MLN8237 and equally potent to 
VX-680. So basically both 21 and 25 act as a pan-AKI, 21 just needs more than five-
fold higher concentration to inhibit Aurora A and ten-fold to inhibit Aurora B. 
However, both compounds had similar potency on Aurora B in in vitro kinase assay and 
21 is more soluble than 25 which is counterintuitive. The reason of this discrepancy –
again – might be their different physicochemical properties, metabolism and secretion in 
cancer cells. Unfortunately we had no possibility to determine any of these properties. 
 
Final speculations about the properties of benzotiophene-3-carboxamides 
After the admittedly incomplete characterisation of benzotiophene-3-carboxamides it is 
worth to contemplate the whole picture again: 
The cell viability inhibition IC50 value of 25 is higher than the one in in vitro kinase 
assay. WB also corroborates that at the cellular IC50 values (300 nM, 3 h) both Aurora 
kinases were already blocked. While in flow cytometry apoptosis started only after 72 h, 
compound concentration was also less (100 nM). Whether apoptosis starts at 300 nM 
already after 48 h (or less) is not sure. It is well-known though that the MTT method 
cannot differentiate why the treated cell culture is less “viable”. Phenomena like 
cytokinesis inhibition and polyploidy (in case of Aurora B inhibition), or apoptosis of 
dividing cells (due to inhibition of Aurora A or off-target kinases) or simply ceased cell 
division (quiescence – G0, or senescence) all can give the same decrease in cell 
viability. That is why MTT assay is less and less utilised nowadays. Therefore, besides 
Aurora kinases another source of cell viability inhibition observed at the cellular IC50 
value of 25 is very likely due to off-target kinases. Main off-targets of 25 are receptor-
kinases (AXL, VEGFR2, PDGFR-b, DDR1) known to malfunction in many cancer 
types (e.g. VEGFR2 in HCT 116 – see above), or c-Src whose simultaneous inhibition 
with aurora kinases is synergistic.417 According to their kinase inhibition profile both 21 
and 25 have more off-targets than VX-680. At first glance 21 seems to be the more 
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selective inhibitor to Aurora A, but the fact that it was screened at 1 µM while 25 is at 
10 µM surely makes comparison hard. Of course, it cannot be excluded that cell 
viability inhibition effect of 25 is also a consequence of its Aurora A inhibition at the 
cellular IC50 value (300 nM). 
In case of 21 another explanation is needed. 21 was just as potent in cell viability 
experiments as 25, albeit it starts to block Aurora A only at 500 nM (maybe less) and 
Aurora B at 1 µM. So at the cellular IC50 value of 21 (~300 nM) Aurora B is not 
inhibited. Considering the alike in vitro kinase inhibition values of 21 and 25, a feasible 
explanation might be to the decreased potency of 21 in cell-based assays its attenuated 
intracellular concentration (lower permeability or more active metabolism or higher 
susceptibility to drug-efflux pumps). However, the fact that MLN8237 blocks Aurora A 
at 100 nM after 3 hours but its more paralogue selective derivative (MLN8054) does not 
induce apoptosis even after 72 hours does not support the role of Aurora A inhibition in 
our system. MLN8054 (and presumably also MLN8237) is reported to induce weak 
apoptosis at 250 nM even after 24 hours. The same phenomenon might be the case 
regarding 21. According to the kinase selectivity panel, Aurora A is the main target of 
21. At its cellular IC50 value the effect of 21 might be the result of selective Aurora A 
inhibition. Unfortunately excessive investigation of a less effective compound was not 
priority during our work, so I did not perform apoptosis measurements at 300 or 500 
nM. Besides the possible effect of 21 on Aurora A at the cellular IC50 value, the 
influence of off-target effects might be equally important (like in case of 25 – 
considering their similar structure). 
Fortunately, other Aurora A selective inhibitors may give some clue to assess the 
importance of Aurora A inhibition in my experiments. For example in HCT 116 cell-
based experiments the Aurora A inhibitor ENMD-2076 had an IC50 value of 200 nM 
and inhibited cellular Aurora A from 200 nM and Aurora B from 1 uM. So Aurora A 
inhibition was sufficient to induce apoptosis in that case. At the same time, ENMD-
2076 is also a multi-kinase inhibitor – it has activity also on VEGFR and Src (similarly 
to 25 – which might point to the similar ATP-binding pockets of these kinases) former 
being a driver of HCT 116. So off-target inhibition surely adds to the effect of ENMD-
2076.418  
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However, in xenograft experiments effective doses of MLN8054 and MLN8237 
transiently also inhibited histone H3 phosphorylation – so Aurora B as well.419 Also 
MLN8054 is selective to Aurora A at 1 µM and induces weak apoptosis even at 250 nM 
after 24 hours, but inhibits also Aurora B at 4 µM in HCT 116 cells.321  
Likely, MK-5108 is more potent on Aurora A (0.04 nM) than on Aurora B (~10 nM) in 
vitro, still in cell viability experiments first signs of apoptosis rose only 48 hours later 
and after 72 hours also histone H3 phosphorylation decreased – a sure sign of decreased 
Aurora B activity.420 
These aforementioned examples highlight that even in case of the most selective Aurora 
A inhibitors, the influence of Aurora B cannot be excluded – particularly in in vivo 
animal models where treatments usually longer. Furthermore, it is worth to mention 
again, that also Aurora A inhibition takes ~18 hours to show any effect: cells first exit 
mitosis and undergo cytokinesis then apoptosis.421 Meanwhile also off-target inhibition 
of Aurora B has a chance to take effect. Provided further advances in the field of AKI 
development underline Aurora A as the better target, then 21 might serve as an origo for 
further work. 
However, in our experimental systems decreased activity of Aurora B precisely 
accompanied apoptosis, while of Aurora A did not. Therefore I concluded that 25 was 
the lead molecule of all benotiophene-3-carboxamides in the NCL™ of Vichem Ltd. So 
in the last experiment only 25 was applied. 
 
Trying out compound 25 in drug combination experiments. 
As discussed earlier, combination of anti-cancer drugs is nowadays a very promising 
therapeutic approach. However, assessing whether a drug combination has better than 
additive effect – that is, the two drugs synergize – is a surprisingly difficult 
mathematical question.422 In the last decades several models were developed to answer 
this question and quantify experimental results.423 The most widely accepted algorithm 
is defined by Chou and Talalay.424, 425 They also developed a free software tool – called 
CompuSyn®– based on their algorithm. So in the last round of experiments I tested the 
lead AKI 25 and the reference compound VX-680 in a concurrent treatment with other 
targeted agents. Eight drugs were applied alone or in 1:1 combination to HCT 116 and 
HT-29 colon carcinoma cell lines. The first six drugs were previously reported to 
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synergize with Aurora inhibitors (see chapter 1.3.5.) so they served as point of 
reference. Crizotinib (as a c-Met–ALK dual inhibitor) and – obviously – the in-house 
compound 34 have never been combined with AKIs before. I used two cell lines to test 
the influence of different mutational background on the results. 
- GSK2126458, a PI3K/mTOR inhibitor 
- Erlotinib, an EGFR inhibitor 
- Trichostatin A, a Class I and II histone deacetylase inhibitor 
- Dasatinib, a BCR/Abl and Src family KI 
- Lonafarnib, a farnesyltransferase inhibitor 
- Carfilzomib, a proteasome inhibitor 
- Crizotinib, the ALK, ROS1 and c-Met inhibitor. 
- Compound 34, the in-house EGFR–c-Met dual inhibitor 
According to the calculated CI values I concluded that 25 behaves very similarly to VX-
680 in the drug combination setups. Both AKI showed synergism with most drugs – I 
could reassert most of the previously reported drug combinations. In case of 
GSK2126458 and Lonafarnib not all cell line and AKI combination proved to be 
synergistic. Moreover in case of combinations with Carfilzomib, I observed strong 
antagonism on HCT 116 cells: the extraordinarily high CI value seems to be an outlier 
at first glance. However, high CI values like this are interpretable, since the antagonism 
scale for CI values is from 1 to infinity.396 The reason of this high CI value is the fact 
that Carfilzomib is an extremely efficient compound that reduced viability of HCT 116 
cells with 93% even at 1.5 nM as monotherapy (HT-29 cells were not as sensitive). In 
combination with an AKI the sum effect decreased and its IC50 value was similar to the 
other combination pairs’. Therefore the huge difference in the effect of Carfilzomib 
mono- and combination therapy resulted in a high CI value. On the other hand I 
experienced weak antagonism and an unambiguous synergism on HT-29 cells. It is hard 
to unravel the mechanisms underlying these results. While both cell lines express 
elevated level of Aurora A, their p53 status is different: the HCT 116 cells express wild-
type p53, HT-29 cells a R273H mutant one.413 It is known that cancer cell lines 
harbouring mutant or overexpressed p53 are more sensitive to AKIs – particularly 
Aurora A selective ones.426 Aurora B inhibition induces polyploidy and apoptosis 
regardless of p53 status. Whereas the Aurora A selective inhibitor MK-8745 (a 
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derivative of MK-5108) induces apoptosis in case of wild-type p53 and polyploidy in 
case of mutant one.421 However, not every mutation of p53 created equal: R280K 
mutation increases Aurora A expression while R175H does not.114 Furthermore p53 null 
subclones of HCT 116 cells are not sensitive to inhibition of proteasome at all.427 So the 
p53 status (R273H mutant) might explain why HT-29 cells were not as sensitive to 
Carfilzomib monotherapy and why I got lower CI values for the combinations. What 
sure is that the p53 mutant HT-29 was more sensitive to VX-680 monotherapy than the 
wild-type p53 HCT 116 cell line in my experiments, which explains why more 
combinations showed very strong synergism on the former. 
The only drug combination which had no precedent in the scientific literature is the AKI 
and c-Met inhibitor pair – certain results only point to the feasibility of it.428 Since the 
CI values of AKI and crizotinib combination were appealing in every setup, I was the 
first to report the potency of this combination. 
As we have seen, both the inhibition of EGFR (by erlotinib) and c-Met (by crizotinib) 
had a synergistic effect with AKI treatment. So I hypothesized whether the in-house 
EGFR–c-Met dual inhibitor 34 would also synergise with the AKIs. As I expected, 
combinations of either 25 or VX-680 with 34 proved to be more effective than using 
either agent alone. 
So in the drug combination experiments the lead molecule 25 proved its AKI properties 
again. Furthermore, my observations underline the observation that that despite same 
histology (colon carcinoma) and common genetic alterations (in this case Aurora A 
overexpression), the different mutational background of cancer cells might profoundly 
alter response to a given drug combination. 
 
Generally, I can conclude that the preclinical studies presented in the Thesis confirm the 
AKI properties of benzotiophene-3-carboxamide derivatives. If these molecules will 
form a basis of further AKI development, of course further experiments (particularly in 
vivo animal models) will be needed. Until that time the selected lead molecule, 
compound 25 remains the most potent dual AKI of this compound family.   
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6. Conclusions 
 
According to my results and the auxiliary experiments I can make the following 
assertions: 
 
I) The completely novel benzothiophene-3-carboxamide scaffold is indeed a promising 
structure for the further development of AKIs. Many benzothiophene-3-carboxamide 
derivatives inhibit Aurora A and B kinase function in in vitro assays, abrogate viability 
and induce apoptosis of human colon cancer cells at concentrations comparable to 
reference compounds. 
 
II) Inhibition of Aurora B kinase and the resulting cytokinesis disruption and 
multinuclear cell state always coincided with apoptosis induction in HCT 116 cells. 
Some of our in-house compounds and published inhibitors selective to Aurora A inhibit 
Aurora B and induce apoptosis only at higher concentrations. Therefore disrupting the 
function of Aurora B is an indispensable property of benzotiophene-3-carboxamides to 
achieve anti-cancer effect in our experiments. 
 
III) Compound 25 is a drug-like multi-kinase inhibitor with strong AKI properties and 
qualifies as the lead molecule of the benzotiophene-3-carboxamide derivative 
compounds of Vichem Ltd. 
 
IV) Also in combination with various targeted agents 25 behaves like an AKI. I 
demonstrated the first time that the combination of a c-Met–ALK inhibitor and an AKI 
can be synergistic in some circumstances. 
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7. Summary 
 
Cancer is one of the most devastating disease for developed societies. In the last few 
decades cancer research made enormous achievements in the field of understanding its 
molecular drivers, diagnosing their alteration at an early stage and inhibiting their 
function in a targeted way. However, a comprehensive and reliable model of the 
network of cancer drivers is still missing and the importance of individual drivers is not 
always clear. Also the repertoire of targeted drugs is very limited. Therefore targeted 
therapies usually fail to cure cancer due to various acquired resistance mechanisms. 
Aurora kinases A and B provide a perfect example: while they don’t seem to be 
infallible drivers, their activity is crucial for cell proliferation and frequently increased 
in cancer cells. Despite many efforts to design specific Aurora kinase inhibitors, most 
compounds have failed in clinical trials and there is still no marketed drug of this kind. 
During a drug development project I excessively investigated a family of small 
molecules based on a completely new, benzotiophene-3-carboxamide core structure. 
Many benzotiophene-3-carboxamide compounds inhibited Aurora A and B kinases in 
vitro, triggered morphological alterations typical for Aurora B inhibition and reduced 
cancer cell viability inducing apoptosis. The most effective, lead compound performed 
equally well to reference aurora kinase inhibitors in all in vitro, in silico and cellular 
tests. 
One current trend to improve targeted therapies is the simultaneous inhibition of more 
than one drivers by multi-target drugs or drug combinations. I also proved that the lead 
compound in combination therapy experiments gives similar results to published 
reference Aurora kinase inhibitors. 
Accordingly, the lead in-house benzotiophene-3-carboxamide compound proves to be a 
potent Aurora kinase inhibitor and qualifies as a new, promising candidate for further 
anti-cancer drug development.  
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8. Összefoglalás 
 
A rákos elfajulások a fejlett országok legmagasabb morbiditású betegségei közé 
tartoznak. Az elmúlt évtizedek hatalmas fejlődést hoztak a rák molekuláris hátterének 
megértésében, korai diagnózisában és célzott terápiás gátlásában. Továbbra sincs 
azonban átfogó és megbízható hálózatos modell ezen molekuláris elváltozásokról és az 
egyes hibák szerepe sem mindig egyértelmű. A rendelkezésre álló célzott hatóanyagok 
száma is korlátozott. Ezért sajnos a jelenleg alkalmazott célzott terápiák túlnyomó 
többsége ellen idővel változatos rezisztencia mechanizmusok alakulnak ki a rákos 
elfajulásban. Jó példák erre az Auróra A és B kinázok: bár nem tartoznak a leginkább 
rákkeltő molekuláris elváltozások közé, funkciójuk elengedhetetlen a sejtosztódáshoz és 
aktivitásuk gyakran emelkedett a rákos  szövetekben. Az elmúlt másfél évtizedben 
számtalan specifikus hatóanyagot fejlesztettek ki a gátlásukra, de sajnos túlnyomó 
többségük elbukott a klinikai vizsgálatok során, tehát még mindig nincs engedélyezett 
Auróra gátló gyógyszer a piacon. 
A Vichem Kft.-vel együttműködésben végzett gyógyszerfejlesztési munka keretein 
belül részletesen megvizsgáltam egy új, benzotiofén-3-karboxamid alapvázú hatóanyag 
családot, mint ígéretes Auróra kinázgátlókat. Kísérleteim eredményei azt mutatták, hogy 
több benzotiofén-3-karboxamid származék valóban gátolta az Auróra A és B kinázok 
működését in vitro. A molekulák egy része pedig kifejezetten az Auróra B kináz 
gátlásra jellemző sejtmorfológiai változásokat hozott létre és apoptózis indukálásán 
keresztül gátolta a vastagbélráksejtek életképességét. A leghatékonyabb vegyület a 
referencia Auróra kinázgátlókkal egyformán hatékonynak bizonyult minden in vitro, in 
silico és ráksejtvonal alapú vizsgálatban. 
A célzott terápiák hatékonyság növelésének egyik iránya több molekuláris elváltozás 
egyidejű gátlása többszörös támadáspontú hatóanyagokkal vagy több egyszeres 
támadáspontú hatóanyag kombinációjával. Ennek szellemében a leghatékonyabb 
vegyületet több célzott hatóanyaggal is kombináltam a sejtes vizsgálatokban és ismét a 
referencia Auróra kinázgátlókhoz nagyon hasonló hatásokat tapasztaltam. 
Összefoglalva, a leghatékonyabb benzotiofén-3-karboxamid származék minden 
szempontból hatékony Auróra kinázgátlónak bizonyult és új, ígéretes kiindulási alapja 
lehet további rákellenes gyógyszerhatóanyag fejlesztési munkáknak. 
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